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ABSTRACT
Women with pregestational diabetes are at a high risk of having babies with
congenital heart defects (CHDs). The mechanisms of CHD induction in the offspring of
women with pregestational diabetes remain elusive. With an ever-increasing rate of
diabetes in young adults, there is a pressing need to understand the underlying
mechanisms and initiate effective preventative strategies. The aim of this thesis is to
study the role of reactive oxygen species (ROS) signalling in heart morphogenesis,
unravel molecular mechanisms of CHDs induced by pregestational diabetes and provide
new insights on potential therapeutic strategies. To this end, a mouse model of
pregestational diabetes induced by streptozotocin was employed. A spectrum of septal,
conotruncal and coronary artery malformation were identified in the offspring of mice
with pregestational diabetes. Reactive oxygen species (ROS) levels were elevated and
glutathione levels were diminished in the fetal hearts of diabetic female mice. Oral
treatment with an antioxidant, N-Acetylcysteine (NAC), significantly diminished the
incidence of CHDs and prevented coronary artery malformation in the offspring of
pregestational diabetic mice. Furthermore, pregestational diabetes reduced cell
proliferation, altered transcript levels, and disrupted epithelial to mesenchymal transition
(EMT) in the fetal heart of pregestational diabetic mice, which were all prevented by
NAC treatment. To further study the role of basal ROS production in embryonic heart
development, a NADPH oxidase Nox2 knockout mouse was utilized. We demonstrated
that loss of Nox2 expression decreased ROS production, and impaired TGF-β/BMP
signalling and endocardial EMT in embryonic hearts. This ultimately resulted in cardiac
septum and valve defects. Thus, under normal physiological conditions ROS production
ii

promotes heart development whereas excess ROS levels during pregestational diabetes
induce CHDs. These studies show maintaining a balance of ROS levels is essential for
normal embryonic heart development in mice. Furthermore, NAC may have a therapeutic
potential in preventing the development of CHDs during pregestational diabetes.

Key words:
Reactive oxygen species, congenital heart defects, pregestational diabetes, oxidative
stress, coronary artery development, endocardial cushion formation, epithelial to
mesenchymal transition.
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1. CHAPTER 1
1.1 PREGESTATIONAL DIABETES
Diabetes is a major health concern worldwide. To date, 382 million people have
diabetes and with an increasing rate of 10 million people annually, the number of diabetic
patients is estimated to reach 592 million by 2035 [1]. According to the Canadian
Diabetes Association, one in every 10 Canadian adult has diabetes. About 3 to 9 women
in every 1000 pregnancies in European or North American populations have diabetes
before pregnancy, which is pregestational diabetes [2-6]. Women with pregestational
diabetes are at risk of having infants with congenital abnormalities in the neural tube,
musculoskeletal, renal and cardiovascular systems [7,8]. Among all types of congenital
abnormalities, congenital heart defects (CHDs), with the prevalence of 3-5 fold higher
than non-diabetic population, are the most common type of abnormalities [9-12].
Clinical studies have shown that maternal high blood glucose levels strongly
correlate with the incidence and severity of congenital defects in the offspring [13-15],
whereas, good glycemic control through insulin injections reduces the incidence of
congenital defects in their offspring [16-18]. Therefore, health policies have been
implemented to spread awareness and encourage diabetic women to maintain good
glycemic control throughout gestation by insulin treatment. Despite these measures, the
rate of congenital defects in pregestational diabetes is still significantly higher than the
normal population [11,19,20]. The reasons, although not completely understood, are
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suggested to be due to failure in maintaining optimal glycemic levels, especially during
early gestational age when organogenesis is occurring [21].
This thesis is dedicated to improve our understanding of the factors that interrupt
fetal heart development due to pregestational diabetes. Specifically, I focused on the role
of increased reactive oxygen species (ROS) levels in induction of CHDs and the
efficiency of an antioxidant in preventing those defects that develop during pregestational
diabetes. Additionally, I demonstrated that basal ROS signalling is required for
embryonic heart development under normal physiological conditions. Overall, my studies
show that maintaining a balance of ROS levels is essential for normal heart development
in mice.

1.2 HEART DEVELOPMENT
The heart is one of the first organs to form and function in early embryonic life
[22]. During development, cardiac progenitors undergo extensive proliferation,
remodeling, migration and differentiation. The process of heart development is precisely
regulated by a combination of transcription factors, signalling molecules and epigenetic
factors [23]. The release of the genome sequence and advances in genetic tools during the
past decades assisted in performing numerous studies on a variety of animal models to
comprehend the sophisticated process of heart formation. Understanding the molecular
mechanism of heart development is essential in order to enhance our perspective of
congenital defects that arise during embryogenesis, and to identify possible therapeutic
approaches to prevent those defects.

2

1.2.1 Origin of Heart Fields
Cardiac progenitors arise from the mesoderm germ layer [24-26]. During
gastrulation, cardiac progenitor cells, which are located in the anterior primitive streak
migrate inward as part of the anterior lateral plate mesoderm (Figure 1.1 A-B) [27,28].
This migration results in formation of two lateral heart fields along the midline that
express early cardiac markers. The lateral heart fields then expand across the midline to
form a crescent-shaped cardiogenic plate (Figure 1.1 C). Subsequently, the two edges of
the crescent-shaped structure will migrate towards the midline and join to form a tubular
heart by E8 in mice (Figure 1.1 D). At this stage, slow peristaltic contractions are
initiated [29,30]. The heart tube is composed of two concentric layers: the endocardium
and myocardium, which are separated by a layer of extracellular matrix, termed the
cardiac jelly. Structurally, the anterior end of the heart tube is linked to the arterial trunk
and the posterior end is linked to the venous channels. In this system, blood drains from
the venous channels into the atrium chamber then flows to the ventricular chamber and is
directed out via the arterial trunk (Figure 1.1 D).
Cardiac precursors rise in a temporal and spatial manner to contribute to
development of a sophisticated cardiovascular system. Extensive analysis has revealed
the origin of cardiac precursors, their molecular interactions and contribution to
formation of cardiovascular structures. The earliest anatomical studies marked the cardiac
crescent as the origin of cardiac precursors. However, further studies revealed that
disruption of the cardiac crescent did not ablate heart tube formation [31]. This, in
addition to specific expression domains identified by gene trap experiments [32], led to
further studies to identify other potential heart fields and subsequently, a distinct
3

population of cardiac progenitors that are located on the dorsal and anterior side of the
cardiac crescent was identified. Thus, the precursors located at the cardiac crescent were
called the primary or first heart field (FHF) and the cells located on anterior-dorsal site of
cardiac crescent were called the second heart field (SHF) (Figure 1.1 C). Lineage tracing
experiments demonstrated participation of FHF cells to formation of the primary heart
tube. Concurrent with formation of the heart tube, SHF cells will migrate into the venous
and arterial channels of the heart tube and contribute to the heart tube’s elongation [3133]. In particular, FHF progenitors contribute to formation of the left ventricle and atria
while the SHF lineage contributes to formation of the right ventricle [34], interventricular
septum, the outflow tract (OFT) at the arterial pole of the heart, and portions of both atria
[33] (Figure 1.1 E-F). Followed by elongation of the heart tube and cardiac looping, a
group of cells arising from the cardiac neural crest will migrate from the dorsal neural
tube structures through the pharyngeal arch toward the OFT of the looped heart (Figure
1.1 E-F) [23,35]. Cardiac neural crest cells will then assist in remodeling of semilunar
valves, formation of cardiac vessels and septation of the OFT (Figure 1.1 G).

1.2.2 Heart looping
As the heart tube elongates the common ventricular chamber bends ventrally and
dorsally and then moves to the right, thus forming a looped heart tube (Figure 1.1 E).
The process of heart looping occurs during embryonic day (E) 8.25 to E10.5 in mice and
day 22 to 32 in human embryos [36]. Rightward heart looping that is essential for proper
orientation of the atria and ventricles is directed by left right differences in embryo.
During cardiac looping the atrial end will locate dorsal-cranially and shift to the left side

4

Figure 1.1. Development of the mammalian heart.
Early cardiac precursors (orange) at the primitive streak (A), lateral plate mesoderm (B)
and cardiac crescent (red and yellow) (C). The SHF (yellow) is located anterior and
dorsal to the heart tube (D). Arrows indicate direction of SHF cells migration to the heart
tube. Followed by SHF cell migration, the heart loops to the right and cardiac neural
crest cells (blue) will migrate towards the OFT (E). Primary left and right atria and
ventricular chambers appear (F). Further remodelling and growth of the heart will form a
four-chambered heart (G). A: Anterior, P: Posterior, R: Right, L: Left. Adapted with
modifications from Srivastava, et al. Cell 2006, 126(6):1037-1048.
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of the body, leading to formation of the right and left atrium [37] (Figure 1.1 H). Heart
looping positions the ventricles posteriorly and connected to the common OFT [38].
Although the molecular regulators of cardiac looping are not well known, differential
gene expression in cells of inner and outer curvature of the looped heart suggests that
cardiac looping is driven by intrinsic signalling [39]. In addition, concurrent
incorporation of SHF cells into the heart tube and rightward looping indicates a possible
role of SHF in cardiac looping. Followed by heart looping, development of the septal
walls along the atria, ventricle and OFT is initiated to partition the heart into a fourchambered structure with distinct inflow and outflow vessels.

1.2.3 Septation of Ventricles and Atria
Septation of the atria and ventricular chambers occurs during E9.5 to E14.5 in
mice and during the 5th to 7th week of gestation in humans [36,40]. The ventricular
septum of the adult heart has two parts: the muscular and membranous septum. At E10.5
in mice, septation of the common ventricles initiates followed by ingrowth of muscular
septum from the ventricular wall towards the base of the heart. The muscular septum
does not fuse to the base of the heart at this stage, thus leaving an opening between the
two ventricular chambers at the AV canal. This opening will close after formation of the
membranous septum along the AV canal.
An essential process in septation of AV canal is the development of the
endocardial cushion. The endocardial cushion develops followed by heart looping, when
the myocardium initiates deposition of extracellular matrix in regions of AV canal and
OFT. Accumulation of specialized ECM, the cardiac jelly, between the myocardial and
endocardial cell layer results in formation of bulging acellular structures. Subsequently,
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endocardial cells of the cardiac cushion undergo epithelial to mesenchymal transition
(EndMT) and migrate toward the cardiac jelly, forming the cellular structures termed the
endocardial cushion [41]. The endocardial cushion that forms between the dorsal and
ventral sides of the AV canal is called the AV cushion, which will participate in atrial and
ventricular septation (membranous septum), as well as AV valve formation [41].
Therefore, proper development of the endocardial cushion is a critical process for
formation of a functional cardiovascular system.
Septation of the atrium chamber occurs after development of two parallel septal
structures called septum primum and septum secundum [36,41]. Formation of septum
primum initiates at E9.5 in mice by outgrowth of a thin interatrial membranous septum
on the dorsal side towards the AV cushion (Figure 1.2 B). On the edge of the septum
primum a distinct cell layer forms a mesenchymal cap[36]. The septum primum and
mesenchymal cap will grow towards the AV cushion but will not fully fuse with the AV
cushion. Thus, it leaves an opening between the atrial chambers at the site close to the
AV cushion (Figure 1.2 C). This opening is called the foramen primum and it allows
blood shunting between the atria chambers (Figure 1.2 C) [36]. The foramen primum
will fully close in the fetal heart after fusion of the septum primum to the endocardial
cushion at E12.5 (Figure 1.2 D). However, before closure of the foramen primum, a new
foramen appears by programmed cell death (apoptosis) in the anterior side of the septum
primum (Figure 1.2 C) [36]. This opening is called the foramen secundum and it enables
a continuous passage of blood between the atria when the foramen primum is closed
(Figure 1.2 D). At E13.5, the septum secundum grows on the right side of septum
primum (Figure 1.2 E). Septum secundum is a thick muscular structure, which originates
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from the anterior region of the right atrium [36]. Growth of the septum secundum covers
the foramen secundum but does not fully cover the posterior inferior surface of the
septum primum, leaving an opening that is called foramen ovale (Figure 1.2 F) [36]. The
physiological significance of foramen ovale will be discussed in the fetal heart
physiology sections.

Figure 1.2. Formation of atrial septum.
A) Four-chambered heart structure prior to septation. Note blood flows from both atria to
the left and right ventricles. Blood from both ventricles flows to a common outflow tract
(OFT). B-F) Lateral view of atria and ventricle demonstrates stages of atrial septum
development. Refer to the text for detailed explanation. A: atria, EC: endocardial
cushion, FO: foramen ovale, FP: foramen primum, FS: foramen secundum, LA: left atria,
LV: left ventricle, MC: mesenchymal cap, OFT: outflow tract, RA: right atria, RV: right
ventricle, SP: septum primum, SS: septum secundum, V: ventricle. Adapted with
modifications from Sylva, et al. Am J Med Genet A 2014, 164A(6):1347-1371.
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1.2.4 Septation of the Outflow Tract
Early in heart development, the right and left ventricles share a common OFT
called truncus arteriosus. Septation of the truncus arteriosus begins at E9.5, dividing it
into the aorta and pulmonary artery by E14.5 [42]. During OFT septation, a spiral septum
forms in the midline of the truncus arteriosus and will grow down towards the
interventricular septum and fuse with it [36,42]. This process will form an entwined
structure of aorta and pulmonary artery which links the aorta to the left ventricle and
pulmonary to the right ventricle. The OFT septum creates two same size arteries with
dorsal-ventral orientation [42]. Loss of the dorsal-ventral patterning results in abnormal
connection of aorta and pulmonary arteries to ventricular chambers. These malformations
will be discussed in details in future sections.

1.2.5 Physiology of Fetal Heart
Due to the fetus’ dependence on the mother’s circulation, fetal blood circulation
differs from postpartum circulation [43]. In the adult heart, deoxygenated blood flows
from the inferior and superior vena cava to the right atrium and is pumped into the right
ventricle. Venous blood in the right ventricle is then pumped to the pulmonary circulation
via the pulmonary artery. Oxygenated blood from the lungs flows back via pulmonary
veins to the left atria, pumped into the left ventricle and then ejected to systemic arteries
via the aorta to distribute to all body organs [43]. In the fetus, oxygen is transferred via
the placenta since the lungs are not functionally active. Thus, the fetal heart develops
structural adaptations, called shunts to pass blood in different directions. An important
blood shunt in the fetal heart is the ductus arteriosus that links the pulmonary artery to the
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aorta. Fetal oxygenated blood received from placenta flows via the umbilical veins
through the interior vena cava to the right atrium and then some is pumped to the right
ventricle. When the right ventricle pumps blood towards the pulmonary artery, most of
the blood is shunted through the ductus arteriosus and into the dorsal aorta due to the
high-pressure resistance of the pulmonary artery. During fetal development, high oxygen
tension and prostaglandin levels secreted from the placenta keep the ductus arteriosus
opened [44]. The other important fetal shunt is the foramen ovale that shunts blood
between the right and left atria. Increased pressure of right atria passes some of the
oxygenated blood via the foramen ovale to the left atria. Following the first breath, the
neonate’s lungs inflate and resistance in the pulmonary veins will significantly decrease,
allowing more blood flow to the pulmonary circulation. In addition, due to reduced
oxygen and increased pressure in the left atria, the septum secundum covers the foramen
ovale and blocks atria blood shunt. Within hours to days after birth, with reduction of
prostaglandin levels in the neonate, the ductus arteriosus is closed to avoid the mixture of
oxygenated and deoxygenated blood [44]. Therefore, partitioning of the heart is
functionally complete.

1.2.6 Molecular Regulators of Early Heart Development
1.2.6.1 Nkx2.5
One of the early markers of cardiomyocyte specification is Nkx2.5 (NK2
transcription factor, locus5) that is expressed in the cardiac crescent (starting at E7 in
mice) and in their myogenic descendants [45,46]. Although the homologue of Nkx2.5 in
Drosophila, Tinman, is essential for heart tube formation [47], Nkx2.5 expression in mice
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is dispensable for heart tube formation [48], but it is specifically required for left
ventricular chamber development [49]. Nkx2.5 is a DNA binding transcription factor that
is expressed in both FHF and SHF during embryogenesis and demonstrates robust
expression in adult cardiomyocytes as well [45,50,51]. Importantly, Nkx2.5 regulates
expression of cardiac genes that determine terminal differentiation of cardiomyocytes
[52]. Additionally, Nkx2.5 is robustly expressed in specialized cardiac conducting cells
during embryogenesis, suggesting its possible role in development of the conduction
system [53]. Nkx2.5 null mice demonstrate impaired cardiac morphogenesis including
reduced myocardial growth and trabeculation [52]. Therefore, loss of Nkx2.5 results in
arrest of heart development in early stages of embryonic development after heart looping
[48,52].
1.2.6.2 GATA 4, 5, 6
The GATA family is a group of zinc finger transcription factors, which interact
with the guanine-adenine-thymine-adenine (GATA) binding site of DNA to regulate
expression of downstream genes. Six isoforms of the GATA transcription factor have
been identified in vertebrates, three of which are expressed in cardiac progenitors:
GATA4, GATA5 and GATA6 [54]. GATA4 is expressed in embryonic and adult
cardiomyocytes [55,56]. Although, GATA4 expression is not critical for cardiac lineage
specification [57], loss of Gata4 in endoderm is lethal due to impairment of cardiac
morphogenesis [58,59]. Specifically, in Gata4 null mice, the lateral cardiac crescents fail
to fuse, thus the heart tube will not form, leading to formation of cardiac bifida [58,59].
In addition, GATA4 directs transcriptional activation of factors that regulate
cardiomyocyte proliferation and differentiation [60,61]. Furthermore, epicardial
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expression of GATA4 and GATA6 are essential for development of endocardial cushion
and cardiac vasculature [62,63]. GATA5 expression in the heart is identified as early as
E9.5 in endocardial cells and later on in the endocardial cushion up to E12.5 in mice [64].
GATA5 plays a critical role in endocardial differentiation, aortic valve development and
through interaction with GATA4 and GATA6, it contributes to formation of the OFT [6466]. In addition to their role in regulation of cardiac development, GATA4 and GATA5
regulate cardiomyocyte proliferation cooperatively [67]. There have been limited
numbers of studies on the role of GATA6 in mammalian heart development. Early
investigation demonstrated that GATA6 expression is essential for development of extraembryonic tissues at early embryonic stages, and full body knockout embryos die before
implantation [68]. Studies in amphibians demonstrated that GATA6 is required for
cardiac maturation, and its loss in cardiac progenitors delays cardiomyocyte terminal
differentiation [69]. Notably, GATA4 and GATA6 double mutants demonstrate loss of
cardiac differentiation resulting in acardia phenotype in mice [70]. With recent reports of
GATA6 mutations in cases with CHDs, a more thorough analysis of GATA6 function in
heart development is essential [71,72].
1.2.6.3 TBX5
TBX5 (T-box 5) transcription factor expression is observed in the cardiac crescent
as early as E8 in mice, and then it is observed in the posterior part of the linear heart tube,
corresponding to the region that will form the future sinus venosus and atria. TBX5
expression in the myocardium of the linear heart tube will become more robust and
restricted to the left ventricle as the heart tube loops to the right. The asymmetric pattern
of TBX5 expression persists up to E11.5, leaving no expression in the right ventricle and
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OFT. At E13.5, expression of TBX5 will be more robust in the left superior vena cava,
atria walls, septum primum and secundum [73,74]. Tbx5 null mutation disrupts
expression pattern of several genes including Gata4, resulting in hypoplasia of the
primitive atria, inflow tract and left ventricle, leading to arrest of cardiac development by
E9.5 [75]. A 50% reduction of Tbx5 mRNA levels in Tbx5+/- mice caused defects in
formation of atrial septum secundum and primum and occasionally defects in the
ventricular septum.
1.2.6.4 MEF2
Monocyte enhancer factor 2

(MEF2) is a transcription factor that binds to

adenine-thymine (AT) rich DNA domains to regulate expression of muscle specific genes
[76]. In the mouse MEF2 family, there are four genes: Mef1A, Mef2B, Mef2C and Mef2D.
Although all of the genes are expressed during early heart development, Mef2C received
considerable attention as the first Mef2 factor to be expressed in cardiac precursors and its
requirement for heart looping [77,78]. SHF precursor cells residing medial to the cardiac
crescent express MEF2C and this expression will continue in the OFT and right ventricle
[79]. Null mutations in Mef2c results in impaired heart looping, absence of right ventricle
formation and reduced expression of cardiac alpha-actin [78]. Expression of Mef2C is
regulated through specific interactions of transcription factors GATA4 and ISL1 with its
promoter [79].

1.2.7 Transcription Factor Interactions
Regulation of heart development by transcription factor activity is a sophisticated
phenomenon. Often individuals with mutations in different transcription factors
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demonstrate the same cardiac abnormality. As an example, mutations in Gata4, Nkx2.5 or
Tbx5 may manifest as septal defects in the atria or ventricles or other CHDs that are often
associated with conduction defects [23,80,81]. There has been accumulating evidence
that transcription factors work in combinations to activate expression of downstream
genes. As an example, functional interaction of NKX2.5 with TBX5 or GATA4, and
functional interaction of GATA4 with TBX5 has been demonstrated to be essential for
regulation of downstream genes controlling cardiomyocytes differentiation or septal
development [82-84]. Moreover, cardiac transcription factors may activate transcriptional
expression of their cofactors. As an example, GATA4 activates transcriptional expression
of Nkx2.5 through interaction with the GATA binding sites on the Nkx2.5 promoter
region [85] and Nkx2.5 activates expression of GATA6 through interaction with its
promoter [86]. Thus, when analyzing the genetics of CHD, a sophisticated model of
interacting transcription factors should be considered.

1.2.8 Regulators of Endocardial Cushion Development
Endocardial cushion development is critical for normal heart development and its
malformation is associated with severe septal and valvular defects [87]. Formation of
cellular structures in the endocardial cushion is initiated by activation of endocardial cells
to undergo epithelial to mesenchymal transition (EndMT).

This process has three

essential stages: 1) activation of endothelial cell transformation in response to paracrine
and autocrine signals from the myocardium and endocardium, respectively, 2)
modulation of cell-cell adhesion and acquisition of a mesenchymal phenotype, and 3)
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migration and residing in the cardiac cushion. The following is a description of growth
factors and signalling molecules that are essential to form endocardial cushion structures.
EndMT is initiated upon receiving signals from the myocardium [88]. The two
important classes of signalling molecules in the initiation of EndMT are bone
morphogenic proteins (BMPs) and transforming growth factor β (TGF-β) that are
members of the TGF-β superfamily. There are three isoforms of TGF-β: TGF-β1, 2, and
3. Around the time of endocardial cushion development, TGF-β1 shows ubiquitous
endocardial expression that will gradually be restricted to endocardial cells at the AV and
OFT [89]. TGF-β2 expression is restricted to the OFT and AV myocardium. TGF-β3
expression is not detectable until after formation of the cardiac cushion, and it is
expressed in the myocardial as well as in endothelial and mesenchymal cells [90-92]. Due
to the broad activity of the TGF-β family during early embryogenesis, null mutations in
Tgf-β1 [93-95], Tgf-β2 [96] and Tgf-β3 [97,98] cause a wide range of developmental
defects and early lethality in mice. Therefore, most studies on TGF-β regulation of EMT
have been performed on endocardial cushion explants. These studies demonstrated that
addition of either TGF-β2 or 3 or a combination of both stimulates EndMT induction in
chick AV explant culture [92,99,100]. However, the significance of TGF-β isoforms
varies in different species. In contrast to observations in chicks, TGF-β3 knockout mice
do not exhibit overt endocardial cushion defects [97], and the role of TGF-β2 in the
regulation of EndMT seems to be more prominent [101]. Differences in the temporal and
spatial patterning of TGF-β2 and 3 expression suggests that TGF-β2 and TGF-β3 are
sequentially and separately involved in the process of EMT in mice. While TGF-β2
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mediates

the

initial

endothelial cell-cell separation,

TGF-β3 is

required

for

the cell morphological changes that enable migration of cells into the underlying
extracellular matrix [102].
The BMP family has numerous isoforms with distinct or overlapping functions.
The important BMP ligands that participate in endocardial cushion formation are BMP2
and BMP4 that are expressed in the myocardium of the AV cushion in the same temporal
and spatial pattern as TGF-β expression [103,104], indicating functional interaction
between TGF-β and BMPs. Knockouts of Bmp2 or Bmp4 are both embryonic lethal
before E9.5 making in vivo analysis difficult to perform [105,106]. However,
development of antisense technology has made it feasible to examine the significance of
BMPs in the regulation of EndMT [107]. These experiments demonstrated that although
BMP2 is required for the initiation of EndMT, it is not sufficient to induce EMT in
endocardial cells. These studies also demonstrated that BMP2 acts synergistically with
TGF-β3 in the induction and regulation of EMT [108,109].
A common mediator of BMP and TGF-β signalling in the regulation of EndMT is
the SMAD protein family [110,111]. Through distinct signalling pathways, both BMP
and TGF-β phosphorylate and activate different family members of SMADs, which leads
to nuclear localization of SMAD4 for regulation of downstream target genes such as
Snail1, an important regulator of cell migration [112,113]. Another pathway that
regulates Snail1 expression is the Notch1 signalling pathway that works in parallel with
TGF-β in regulation of EndMT. Notch1 is expressed in endocardial cells and promotes
TGF-β2-induced EMT through transcriptional activation of Snail1 expression [114,115].
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Mutations in NOTCH1 or its ligand (DELTA or JAGGED) are associated with aortic
valve or OFT defects, respectively [116,117].
Apart from differentiation, proliferation of endocardial cells is an essential part of
endocardial cushion formation. Vascular endothelial growth factor A (VEGF-A) is an
important growth factor that is expressed in endocardial and myocardial cells during early
embryogenesis. During heart development, VEGF-A expression is gradually restricted to
endocardial cells adjacent to the AV cushion and OFT region [118]. Myocardial
overexpression of VEGF-A at E9.5 inhibits endocardial cushion formation in mice and
induces CHDs [119]. Additionally, overexpression of VEGF-A in endocardial cells in
mice resulted in severe abnormalities in ventricular septation and OFT remodelling,
causing embryonic lethality by E12 to 14.5 [120]. NFAT (nuclear factor in activated T
cells) is a transcription factor that is expressed in endocardial cells covering AV cushion,
and it is crucial for endocardial cushion development [121,122]. Loss of NFATc1 in mice
results in defects of endocardial cushion development, as a result of impaired cell
proliferation. Importantly, VEGF is upstream regulator of this NFAT activation and
nuclear localization [88,123]. Overall, these studies suggest that VEGF-A is an important
regulator of endocardial cushion development and any alterations in VEGF-A dosage
impairs cardiac development [88].

1.2.9 Morphological Aspect of Coronary Artery Development
The coronary vasculature originates from the ascending aorta at the sinus of the
aortic valves to distribute oxygenated blood to the heart [124]. Coronary arteries branch
from the base of the aorta and travel along well-defined paths to reach the cardiac apex.
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Arteries form a vascular network to ensure an efficient supply of oxygenated blood to the
myocardial cells. Deoxygenated blood is collected into capillary veins, which drain into
the right atrium, inferior to the opening of superior vena cava. Structurally, coronary
arteries are composed of three cell layers: endothelium, smooth muscle cells and
fibroblasts. In the following, I will describe the process of coronary network formation
during embryogenesis.
The coronary network in the myocardium forms during two processes:
vasculogenesis and angiogenesis [125]. Vasculogenesis refers to de novo formation of the
primitive vessels network and angiogenesis refers to growth and remodeling of the
primitive network into a complex network. During heart development, vasculogenesis
initiates after the formation of an epicardial cell layer at E10.5, followed by development
of the vascular network through the process of angiogenesis. Here, I will review the
morphological aspects of vasculogenesis in the embryonic heart and then describe
essential molecular factors in the regulation of coronary artery formation in the heart.
Early precursors that participate in the formation of the vascular network in the
heart emerge from outside of the heart field around E9.5 in mice [126], form a structure
called the proepicardium organ (PEO). The PEO are a group of cells that emerge from a
region close to the sinus venosus and the liver primordium. During E9.5 to E10.5 in mice,
cells of the PEO migrate toward the heart and proliferate to expand over the myocardium
and form the epicardial cell layer [127-129]. While epicardial cells proliferate to cover
the myocardium, some of the epicardial cells undergo epithelial to mesenchymal
transition (EMT) and dissociate from the epicardial cell layer to invade the myocardium
[130]. Cells of epicardial origin that undergo EMT are called epicardial derived cells
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(EPDCs). EPDCs primarily reside in the subepicardial space and after migration into the
myocardium, they differentiate into a variety of cell types including smooth muscle cells,
perivascular and interstitial fibroblasts [131-133]. The endothelial capillary network
works as a scaffold for EPDCs, where they differentiate into smooth muscle cells and
fibroblasts to establish the coronary artery network at E14.5. Interaction of smooth
muscle cells and endothelial cells is critical since vessels will regress easily if they are
not covered with smooth muscle cells [134].
The developmental origin of coronary endothelial cells has been the subject of
many experimental studies and still remains a controversial issue [135-137]. Primarily,
endothelial progenitors have been reported in the subepicardial space, growing into the
myocardium and eventually connecting to the aortic root [138-140]. Studies on quailchick chimera embryos demonstrated that coronary endothelial cells emerge from the
PEO, where they arise as EPDCs and form primary endothelial tubes in the myocardium
[136,141-143]. However, this developmental model was later challenged in epicardial
lineage tracing studies of mice where very few Wt1+ and no Tbx18+ EPDCs in the
myocardium obtained an endothelial cell fate [137,144]. Recent studies have provided a
better understanding of endothelial cell origin by demonstrating that endothelial cells
originate from the endothelial sprouts of the sinus venosus, which is located in the
subepicardial space. Endothelial cells later on migrate into the subepicardial space and
then the myocardium to form the endothelial cell population of coronary arteries
[145,146]. This conflict appeared to be resolved after a group of researchers
demonstrated that a subpopulation of cells from the PEO contribute to the formation of
the sinus venosus and also cardiac endothelial cells [147]. Additionally, fate mapping and
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clonal analysis demonstrated a subset of endothelial cells originated from endocardial
cells [148]. Overall, coronary endothelial cells originate from a mixed precursor
population. Both EPDCs and subepicardial endothelial cells contribute to the development
of coronary arteries with minor contribution from the endocardium.

1.2.10 Molecular Regulators of Coronary Artery Development
Transcription factors, signalling molecules and growth factors that regulate
formation of the epicardium and EPDCs are numerous [149]. Signals that regulate
coronary artery development arise from two sources: epicardial and myocardial cells.
Epicardial and myocardial cells signal to each other to coordinate formation of the
vascular network and growth of the myocardium [150]. It is believed that hypoxia is the
initial signal that drives vasculogenesis. Hypoxia inducible factor 1 (HIF1) is a
transcription factor that is expressed during hypoxia and oxygen levels will alter its
stabilization or degradation [151]. HIF1 will activate transcriptional expression of several
pathways including genes that are involved in angiogenesis, cell proliferation, apoptosis,
glucose metabolism, and cell survival [152,153]. HIF1 transcription factor is composed
of two isomers called α and β, which dimerize for transcriptional activity [154].
Functional studies in embryos revealed high activity of HIF1α in the regulation of
vasculogenesis. Reduced HIF1α expression impairs normal coronary artery development
[155,156]. One of the downstream targets of HIF1α that has a pivotal role in coronary
vasculature formation is Wilms tumor-1 (Wt1) [157]. During cardiac development, Wt1
is a key regulator in the formation of the PEO and epicardial cells [158]. Conditional
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knock out of Wt1 in epicardial cells results in loss of coronary artery development and
fetal lethality between E16.5 to E18.5 [159].
A prominent downstream target of Wt1 in the regulation of epicardial EMT are
the transcriptional factors Snail1 and Slug that belong to the family of zinc finger
transcription factors [159-162]. Slug expression is detected in the PEO, epicardial cells as
well as epithelial and mesenchymal cells in the avian heart [163]. Snail1 expression is not
detected in the PEO but it is present in epicardial and subepicardial cells at E10.5-12.5 as
well as in EPDCs at E14.5-16.5 in mice [164]. Snail1 and Slug promotes EMT through
repressing the expression of E-cadherin, a transmembrane protein that forms cellular
junctions and inhibit cell migration. However, in comparison to Snail, Slug demonstrates
less ability to inhibit E-cadherin expression [162,165].
Retinoic acid (RA), the active derivative of vitamin A, has a prominent role in the
development and growth of the myocardium and coronary vasculature [166]. In
particular, RA signalling mediates vasculature development by maintaining myocardial
and epicardial cell adhesion that is essential for proper signalling between the
myocardium and epicardium. As well, RA signalling promotes epicardial EMT, EPDCs
differentiation and cardiomyocyte proliferation through activation of bFGF secretion
from the myocardium [167,168]. RA depletion during early embryogenesis impairs
growth and development of the early heart tube and also diminishes Gata4 transcriptional
expression [169,170]. In addition, depletion of RA signalling during vasculogenesis
impairs epicardial cell layer formation, myocardial growth and formation of the vascular
network [168,171]. Notably, Wt1 and retinaldehyde dehydrogenase (RALDH2), the
enzyme that catalyzes a critical step in RA production, have an epicardial expression
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pattern [158,172]. Recent studies demonstrated that Wt1 regulates epicardial expression
of RALDH2 [173,174] in the regulation of coronary vasculogenesis in mice [175 ].
Hence, through various mechanisms, RA regulates myocardial growth and vascular
development of cardiac progenitors in the heart.

1.3 CONGENITAL HEART DEFECTS
As discussed in the previous sections, heart development is ruled by precise
regulation of gene expression and signalling molecules. Modifications to gene expression
during heart development will lead to abnormalities in heart structure and impair heart
function. The morphological defects that occur during heart development in embryos are
called congenital heart defects (CHDs). The incidence of CHDs in the general population
is 1-5% [176,177]. With advances in cardiac repair surgeries, many children born with
CHDs will survive to adulthood, thus, genetic factors that induce cardiac defects will be
more likely to be passed onto the next generation [178]. Based on recent reports, the
prevalence of CHDs in infants born to mothers with CHDs is 2-20% [179]. This raises a
public health concern and demonstrates a critical need to understand the underlying
molecular mechanism of CHD and development of preventative and therapeutic
strategies.

1.3.1 Genetics and Environmental Basis of CHDs
Abnormalities in cardiovascular development are caused by inherited or noninherited factors [180,181]. Inherited factors are presented as chromosomal disorders,
Mendelian syndrome or non-syndromal single gene mutations. Chromosomal disorders
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account for 8 to 10% of CHDs, Mendelian syndrome accounts for 3 to 5% of CHDs and
non-syndromal single mutation accounts for a very small population of CHDs [181].
Thus, at present, only about 15% of CHDs can be attributed to a genetic factor while the
cause of the other 85% of CHDs still remains unknown. Non-inherited factors refer to
environmental conditions that increase the prevalence of CHDs in infants. These factors
include maternal alcohol consumption, nicotinic smoke, and maternal illness such as
pregestational diabetes [12]. Collectively, it is speculated that the majority of CHDs have
a multifactorial origin, referring to a combination of genetic and environmental factors.

1.3.2 Types of Congenital Heart Defects
CHDs studied in this thesis can be divided into four groups: septal, conotruncal,
valvular and coronary artery malformations. Septal defects include malformation of the
atrial or ventricular septum. Conotruncal defects include tetralogy of Fallot (TOF),
pulmonary atresia, double outlet right ventricle (DORV), and dextro-transposition of
great arteries (d-TGA or TGA). Cardiac valve defects include malformation of aortic or
atrioventricular valves, and coronary artery malformations include formation of
hypoplastic coronary arteries. The following section is a description of the origin of these
defects and their genetic basis.

1.3.3 Atrial Septal Defects
Atrial septal defect (ASD) occurs when there is a failure in formation of the
septum between the right and left atria, thus blood shunts between atrial chambers. ASD
is a common type of CHDs with a worldwide prevalence of 1.6 per 1000 live births
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[182]. ASD reduces heart function but it is not a cyanotic type of heart defect, meaning
that it does not cause blue coloring of the skin or lips. This is due to the fact that the
higher pressure in the left atrium will direct oxygenated blood into the deoxygenated
right atrium. ASDs may occur in the septum primum or septum secundum. Defects in
formation of the septum primum occur as a result of failure in fusion of the septum
primum to the endocardial cushion. Thus, ASD primum defects may rise due to
decreased cell proliferation of the septum primum or abnormal development of
endocardial cushion [183]. Secundum ASD is persistence of the foramen ovale, which
may occur as a result of inadequate growth of septum secundum or excess apoptosis in
septum primum. As discussed in previous sections, foramen secundum forms by
apoptosis (Figure 1.1). However, excessive apoptosis in the septum primum could result
in an oversized foramen secundum that does not cover up the septum secundum
membrane. Holt Oram syndrome, associated with TBX5 mutation and DiGeorge
syndrome, associated with TBX1 mutation, are both chromosomal abnormalities that
result in ASD secundum defects [184]. In addition, non-syndromal familial single
mutations in NKX2.5 [185], TBX5 and GATA4 [84] are also associated with secundum
defects. Recent reports indicated a molecular interaction of GATA4, NKX2.5 and TBX5,
which is required and critical for formation of the atrial septum [186].

1.3.4 Ventricular Septal Defects
As mentioned before, the ventricular septum is composed of membranous and
muscular structures. The membranous septum is a small part of the ventricular septum
and is located beneath the AV valves at the base of the heart. The muscular septum
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extends from the apical side of the ventricles to the membranous septum. Septal defects
can occur either in the muscular or membranous part of the ventricular septum [187]. The
worldwide prevalence of ventricular septal defect (VSD) is 2.6 per 1000 live births [182].
Interruption in formation of the membranous septum or fusion of the membranous to
muscular ventricular septum results in an opening in the septum that allows blood flow
communication between oxygenated and deoxygenated blood of the two ventricles.
Mutations in NKX2.5 and GATA4 genes have been reported in cases with VSD [188193]. Additionally, Holt-Oram syndrome or TBX5 mutation is associated with VSD [84].
Notably, human genetic studies reported a GATA4 mutation that impairs its functional
interaction with TBX5 and is associated with familial incidence of VSD [84,194]. This
data implies that functional interaction of GATA4, NKX2.5 and TBX5 may be essential
for ventricular septum development.

1.3.5 Atrioventricular Septal Defects
Atrioventricular septal defect (AVSD) or atrioventricular canal defect (AVCD) is
occurrence of an ASD at the site of ostium primum that is higher than the AV valves
accompanied by a membranous VSD [195]. Structurally, AVSD is caused by
malformation of the endocardial cushion and is often associated with abnormal AV valve
(mitral and tricuspid) formation. AVSD has a 48% postnatal mortality rate [196] and with
the prevalence of 0.24-0.31 per 1000 live births, it is considered a rare type of CHD
[197,198]. The incidence of AVSD in neonates with trisomy 21 (Down’s Syndrome) is
17% [199,200]. The genes involved in non-syndromic AVSD include NKX2.5, GATA4,
and TBX5 [201-205]. Although the mechanism underlying this defect is not fully

25

understood, pre-gestational diabetes significantly increases the risk of both syndromic
[206] and non-syndromic complete AVSD [207].

1.3.6 Tetralogy of Fallot
The most common cyanotic defect is tetralogy of Fallot (TOF), which originates
due to malformation of the aorticopulmonary septum. This defect includes four elements:
pulmonary stenosis, right ventricular hypertrophy, overriding aorta and VSD. Pulmonary
stenosis occurs as a result of unequal partitioning of the OFT. Thus, the aorta is wider and
the pulmonary artery is narrowed. The second element of TOF is overriding aorta, which
is the opening of the aorta over both ventricles. Overriding aorta occurs due to
misalignment of the OFT septation which slightly shifts the OFT to the right and it
straddles over both ventricles. The third element of TOF is a VSD, which is due to
abnormal formation of the interventricular septum. The forth element is hypertrophy of
the right ventricle, which is a physiological response to the narrowed pulmonary artery.
Since the pulmonary artery is narrowed it has a higher resistance and the right ventricle
must pump with more force to overcome the resistance, resulting in right ventricle
hypertrophy. The consequence of TOF is shunting of the deoxygenated blood from the
right ventricle to left ventricle through the VSD and misaligned aorta.
TOF is reported in 3.3 per 10,000 live births and corresponds to 6.8% of all types
of CHDs [182,208]. TOF may occur as a result of anomalies in chromosomes 8 and 22
[209,210]. In chromosome 22 anomaly (DiGeorge syndrome), the TBX1 gene lies within
the deleted region. Additionally, TBX1 polymorphism has been reported in individuals
with OFT defects [211]. Single gene mutations in JAG-1, a Notch1 ligand, VEGF-a,
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NKX2.5, GATA4 and its cofactor FOG2, have been identified in individuals with TOF
[181,212-214]. However, these mutations are identified in a limited population of TOF
patients. As an example, only 1-4% of TOF patients have a mutation in the NKX2.5 gene
[215,216] and only 1.3% of TOF patients have mutations in FOG2 [215,217 ].
Additionally, despite a report on VEGF-a mutation in patients with TOF, a recent metaanalysis of a large population of TOF patients did not find a significant contribution of
VEGF-a mutation to the incidence of TOF [218]. Therefore, our knowledge on genetic
regulators of TOF is still limited. The environmental risk factors of TOF include maternal
alcohol consumptions, RA (vitamin A) deficiency and maternal illnesses such as
diabetes, rubella and phenylketonuria [181].

1.3.7 Dextro-Transposition of the Great Arteries
In the normal heart, the aorta originates from the left ventricle and the pulmonary
artery originates from the right ventricle. Septation of the aorta and pulmonary artery
occurs after formation of a spiral shaped aorticopulmonary septum. In the case of dextrotransposition of great arteries (d-TGA or TGA), the aorticopulmonary septum does not
form in a spiral shape and instead it forms a straight septum [182,219]. This division
causes the aorta to open into the right ventricle and the pulmonary trunk to open into the
left ventricle. Consequently, in the case of TGA, the pulmonary artery transfers
oxygenated blood to the lungs and aorta caries deoxygenated blood to the body.
Prenatally, this defect will not cause death due to the placenta blood transfer. Babies with
TGA are born alive due to the opening of the ductus arteriosus, which is a vessel that
links the aorta and pulmonary and allows mixture of oxygenated and deoxygenated
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blood. However, corrective surgery is required otherwise death will occur. The
worldwide prevalence of TGA is 3.5 per 10,000 live births [182,219]. Mutations in
NKX2.5 and NODAL are associated with non-syndromal causes of TGA. Environmental
conditions such as maternal diabetes is a risk factor for TGA [181].

1.3.8 Double Outlet Right Ventricle
Double outlet right ventricle (DORV) occurs as a result of disruption in
remodeling of the OFT. In this type of defect, both the aorta and pulmonary are
connected to the right ventricle. Hearts with DORV have an obligatory VSD for
circulation of blood between the heart chambers. The incidence of DORV is estimated to
be 1.6 per 1000 live births [213]. A small percentage of DORV is associated with
chromosomal abnormalities such as trisomy 18 [181,220] or chromosomal deletion of
22q11 [221-223]. Single gene mutations in NKX2.5 or GATA4 have a rare contribution to
the incidence of DORV [220,224]. Mutation in the GATA4 cofactor, FOG2 was
identified in 15% of patients with DORV [215]. Additionally, DORV demonstrated
strong association with pregestational diabetes [225].

1.3.9 Hypoplastic coronary artery disease
Hypoplastic coronary artery disease refers to abnormal development of coronary
arteries, with marked reduction in the length or diameter of one or more major branches
[226]. This condition may severely affect the heart’s function and results in sudden
cardiac arrest in young or middle age adults [227-231]. Hypoplastic coronary artery is a
silent disease and usually unexpectedly identified during angiography [232] or the
autopsy following sudden cardiac death [233]. The incidence of coronary artery
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anomalies in patients that are suspected for coronary artery obstruction is about 1% [234237]. Our knowledge on the genetic roots or environmental conditions that result in
hypoplastic coronary artery disease is limited. A recent study showed that deficiency in
nitric oxide release from endothelial nitric oxide synthase during heart development
diminishes Wt1 and Gata4 transcript levels and results in formation of hypoplastic
coronary arteries and consequently myocardial infarction in neonatal mice [238].

1.4 MECHANISM OF CHDS IN PREGNANCIES AFFECTED BY
DIABETES
As discussed in previous sections, maternal diabetes before pregnancy elevates
the risk of CHDs in the offspring. A combination of in vivo and in vitro experiments has
been performed to enhance our understanding of the factors that induce congenital
anomalies in pregnancies affected by diabetes. Primarily, studies in the 80’s
demonstrated that the teratogenic effect of diabetes is related to elevation of blood
glucose levels and not decreased insulin levels [239-243]. In vitro, addition of high
glucose interrupted embryonic development and induced major embryonic malformations
[244-246]. Supplementation of insulin-treated serum from diabetic mice to embryonic
cultures reduced congenital malformations but did not prevent the risk of abnormalities
[247,248], suggesting that serum of diabetic mice contains other teratogenic factors that
were not eliminated by insulin treatments.
The predominant form of glucose transportation in the placenta and embryonic
heart tissue is glucose transporter 1 (GLUT1) [249,250] that is independent of insulin.
Females with hyperglycemia will have excess glucose that is freely transported across the
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placenta and metabolized in the embryonic tissue [251]. Increased glucose levels will
increase glycolysis and this will lead to increased levels of NADH and FADH2, which
are the electron donors for the electron transport chain of mitochondria. Increased
mitochondria respiratory chain activity leads to increased oxygen consumption and ATP
production. As a result of this process, superoxide generation that is a by-product of ATP
production will be increased [252,253]. Interaction of superoxide with other molecules
generates a combination of reactive oxygen species (ROS) that are highly reactive and
can damage DNA or proteins. Additionally, diabetes is often associated with attenuation
of antioxidant bioavailability. Overall, this condition that is defined as excess ROS
generation and reduction of antioxidants levels is called oxidative stress and it is
detrimental to embryonic growth, organogenesis and remodelling [254].
In physiological conditions, excess ROS is depleted by an antioxidant defense
system including catalase, superoxide dismutase and glutathione peroxidase. Glutathione
peroxidase is an important antioxidant enzyme in depletion of ROS. In this enzymatic
reaction, glutathione peroxidase breaks down H2O2 to H2O and O2 with the consumption
of reduced glutathione (GSH) and converts it to oxidized glutathione (GSSG) [255]. In
diabetic conditions, due to increased activity of glutathione peroxidase [256], reduced
GSH are mostly oxidized. In addition, de novo GSH synthesis is diminished [256] that
leads to reduced antioxidant capacity. Thus, H2O2 will be converted to hydroxyl radicals
(OH•), which will cause extensive damage to molecular and cellular structures including
DNA and proteins [254]. Overall, several studies have suggested a strong correlation of
hyperglycemia with oxidative stress and congenital defects in embryos. However, the
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specific molecular mechanism that leads to these defects and the potential therapeutic
strategies remained elusive.
Experiments in the late 90’s indicated that oxidative stress plays a major role in
induction of birth defects. Early evidence on the role of oxidative stress in induction of
birth defects appeared following reports that indicated supplementation of superoxide
scavengers

to

embryonic

culture

media

inhibited

malformation

induced

by

hyperglycemia [257]. Specifically, addition of ROS scavengers such as superoxide
dismutase (SOD), catalase and glutathione peroxidase inhibited hyperglycemia-induced
malformation. In addition, another study confirmed that overexpression of SOD led to
reduced fetal malformations in the offspring of diabetic mice [258]. Furthermore,
extensive studies revealed that addition of antioxidants such as vitamin E, C, butylated
hydroxytoluene and GSH-ester to diabetic animals or high glucose cultures reduced the
rate of malformations [256,259-263]. Therefore, these findings strongly implied that
diabetic induced malformations were caused by oxidative stress and decreasing oxidative
stress in embryos could be an important therapeutic approach.

1.4.1 ROS Regulation of Growth and Development
ROS refers to the derivatives of oxygen free radicals including O2– (superoxide
anion), HO– (hydroxyl radical) and H2O2 (hydrogen peroxide) that are produced from
different cellular sources under physiological or pathophysiological conditions [264]. The
main sources of ROS production are: i) mitochondria respiratory mechanism, ii) NADPH
oxidases, and iii) enzymatic activities such as xanthine oxidase and cytochrome p450. In
embryos, a prominent source of intracellular ROS production is NADPH oxidase.
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NADPH oxidase is a holoenzyme complex, with 7 isoforms of its catalytic subunit
including NOX 1-5 and DOUX 1-2 [265]. NADPH oxidase enzyme complex is mostly
localized on the plasma membrane. The produced superoxide may pass through
aquaporin channels in the form of H2O2 and enter the cell to be involved in different
biological reactions.
ROS can mediate a variety of fundamental cellular process such as proliferation,
differentiation, migration and apoptosis [266]. It is suggested that ROS functions as a
classical signalling molecule, where the levels of ROS release determines the cell’s
response. As an example, excess ROS levels induce cellular apoptosis and it is
detrimental to embryonic growth [267-269], whereas, low or basal ROS levels mediates
expression of genes required for differentiation [270] or proliferation [271,272].

1.4.2 Glutathione and Its Precursor N-Acetylcysteine
Glutathione (GSH) is an important intracellular antioxidant with high intracellular
concentration. Structurally, glutathione is a tripeptide that is composed of glutamate,
cysteine and glycine [255]. GSH is the product of two enzymatic reactions that are
mediated by two enzymes: glutamate-cysteine ligase (GCL) and GSH synthase. In the
first reaction, cysteine is conjugated with glutamate by enzymatic activity of GCL and in
the second reaction, glycine is added to glutamate-cysteine by enzymatic activity of GSH
synthase (Figure 1.3). GCL activity is regulated by feedback inhibition of its final
product, GSH [273]. Thus this metabolic reaction is considered as a rate-limiting step for
GSH synthesis. Cysteine is required for GSH production. A major source of cysteine in
humans is through diet or catabolism of proteins or methionine in the liver.
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Figure 1.3. Glutathione synthesis
Through an enzymatic reaction, N-Acetylcysteine (NAC) is converted to amino acid
cysteine (Cys). Addition of amino acids glutamate (Glu) and glycine (Gly) to cysteine
will produce glutathione peptide (GSH). Adapted with modifications from Rushworth
and Megson, Pharmacol Ther 2013, 141(2), 150-9.
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A precursor of cysteine is N-Acetylcysteine (NAC). Structurally, NAC is composed of an
acetyl group attached to the nitrogen atom of the amino acid cysteine (Figure 1.3). Due
to its small molecular size, NAC can cross the placenta and cell membrane.
Intracellularly, NAC exerts its antioxidant effects by reacting with OH• and O2•
[274,275]. In addition, most of the NAC is deacetylated to cysteine and utilized to
replenish GSH levels [276,277]. NAC has a long history in clinical use to overcome
glutathione deficiency in several disease conditions including: pulmonary disease,
acetaminophen (paracetamol) toxicity, neurodegenerative disease and nephropathy [278282]. Overall, these studies reported that the protective effects of NAC are through
attenuation of oxidative stress and apoptosis. Moreover, experimental analysis
demonstrated that the teratogenic effects of diabetic serum or high glucose in rat
embryonic development are prevented by NAC supplementation [283,284]. In addition,
NAC improved neural crest cell migration in a high glucose environment, in vitro and in
ovo [285,286]. Thus, these studies suggest that NAC may exert beneficial effects in
protecting embryos against oxidative stress induced in diabetic conditions.

1.5 OVERALL HYPOTHESIS AND AIMS
Pregestational maternal diabetes is associated with 3-5 fold increased risk of
CHDs in neonates [9-12]. With the ever-increasing population of young adults with
diabetes, our understanding of the molecular causes of birth defects and the therapeutic
strategies to prevent these defects is critical. Accumulating evidence demonstrated excess
ROS production and a reduced antioxidant defense system lead to oxidative stress in
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embryos affected by pregestational diabetes [256-263]. The main goal of this thesis
project is to understand the role of ROS during cardiac morphogenesis in diabetic and
non-diabetic pregnancies. The overall hypothesis of this thesis is that maintaining
proper ROS balance is required for expression of critical factors that regulate
cardiac morphogenesis.
The first aim of this thesis was to characterize CHDs in the offspring of mice with
pregestational diabetes and to further investigate the state of oxidative stress and
molecular mechanisms that are impaired in fetal heart during diabetic embryopathy. We
further investigated therapeutic strategies to prevent CHDs in the offspring of mice with
pregestational diabetes. In Chapter 2, I hypothesized that pregestational diabetes elevates
oxidative stress in embryonic heart, alters cardiac gene expression levels and induces
CHDs in neonates. Furthermore, I hypothesized that treatment of diabetic mice during
gestation with an antioxidant, NAC, will reduce oxidative stress in the embryonic heart,
and restore gene levels to prevent the development of CHDs in the offspring. A
streptozotocin (STZ) induced mouse model was employed to characterize CHDs in the
offspring. We characterized a broad range of defects including septal and conotruncal
defects in the offspring of diabetic females. Both glutathione and ROS levels were
determined in fetal hearts. In addition, cell proliferation and apoptosis, as well as
expression levels of growth factors and transcription factors were assessed. Furthermore,
the effect of NAC treatment in diabetic dams during gestation on fetal heart development
was studied.
CHDs may include abnormal formation of coronary artery structures, leading to
null coronary artery or hypoplastic coronary artery disease [238]. Formation of coronary
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arteries is pivotal for myocardial development and abnormalities in coronary artery
structure elevates the risk of sudden cardiac death in youth [227]. Whether pregestational
diabetes impairs coronary artery development is not known. Therefore, in Chapter 3, I
examined the formation of coronary vasculature in the neonate born to mice with
pregestational diabetes. I hypothesized that pregestational diabetes interrupts formation of
coronary arteries by elevating ROS levels, altering expression levels of genes essential
for vasculogenesis and interrupting migration of progenitor cells that participate in
formation of coronary arteries. To test this hypothesis, formation of the capillary network
and coronary arteries was assessed in the fetal and neonatal hearts of the offspring using
histology and immunostaining. To study epicardial contribution to coronary artery
formation, Wt1-mediated lineage tracing was performed. The expression of genes
essential for vasculogenesis and epicardial cell migration and proliferation were
determined. Additionally, effects of NAC treatment in the diabetic dams on their
offspring’s coronary vasculature development, ROS production, gene expression and
epicardial cell migration and proliferation were investigated.
Excess ROS levels are detrimental to embryonic growth and development [287].
However, the role of basal ROS levels in regulating heart development and growth
remained elusive. In Chapter 4, I investigated the role of basal ROS production in
embryonic heart development. I hypothesized that physiological levels of ROS are
essential for normal heart development in mice. To address this hypothesis, I employed
mice with a deletion in the NADPH oxidase Nox2 locus, which abolishes ROS production
from NOX2 source. Heart morphology was examined for congenital heart defects in
neonates. In vivo cell proliferation, apoptosis and cell density of endocardial cushions
36

were assessed. Additionally, the number of cells undergoing EndMT was studied ex vivo.
Furthermore, the role of the ROS/TGF-β/BMP signalling pathway in the regulation of
EndMT was investigated. Thus, this thesis sought to examine the impact of pathological
and physiological levels of ROS production in heart morphogenesis and their molecular
mechanisms. The ultimate goal of my studies was to provide novel insights in developing
therapeutic strategies in the prevention of CHDs in the offspring of pregestational
diabetes.
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2.1 CHAPTER SUMMARY
Pregestational diabetes is a major risk factor of congenital heart defects (CHDs).
Glutathione is depleted and reactive oxygen species (ROS) production is elevated in
diabetes. In the present study, we examined whether treatment with N-Acetylcysteine
(NAC), which increases glutathione synthesis and inhibits ROS production, prevents
CHDs induced by pregestational diabetes. Female mice were treated with streptozotocin
(STZ) to induce pregestational diabetes prior to breeding with normal males to produce
offspring. Some diabetic mice were treated with N-Acetylcysteine (NAC) in drinking
water from E0.5 to the end of gestation or harvesting of the embryos. CHDs were
identified by histology. ROS levels, cell proliferation and gene expression in the fetal
heart were analyzed. Our data show that pregestational diabetes resulted in CHDs in 58%
of the offspring, including ventricular septal defect (VSD), atrial septal defect (ASD),
atrioventricular septal defects (AVSD), transposition of great arteries (TGA), double
outlet right ventricle (DORV) and tetralogy of Fallot (TOF). Treatment with NAC in
drinking water in pregestational diabetic mice completely eliminated the incidence of
AVSD, TGA, TOF and significantly diminished the incidence of ASD and VSD.
Furthermore, pregestational diabetes increased ROS, impaired cell proliferation, and
altered Gata4, Gata5 and Vegf-a expression in the fetal heart of diabetic offspring, which
were all prevented by NAC treatment. Treatment with NAC increases GSH levels,
decreases ROS levels in the fetal heart and prevents the development of CHDs in the
offspring of pregestational diabetes. Our study suggests that NAC may have therapeutic
potential in the prevention of CHDs induced by pregestational diabetes.
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2.2 INTRODUCTION
Congenital heart defects (CHDs) are the most common birth defects affecting up to
5% of live births in the general population [1]. Pregestational diabetes mellitus, either
type 1 or type 2, increases the risk of CHDs in infants by 3–5 fold compared to nondiabetic pregnancies [2-6]. With an increase in the number of young adults having
diabetes mellitus [7, 8], the incidence of pregestational diabetes and CHDs caused by
maternal diabetes may further increase, with significant social and economic
consequences.
Although factors responsible for the high incidence of CHDs in pregestational
diabetes are still not fully understood, evidence suggests that oxidative stress may play a
role [9, 10]. For example, the antioxidant capacity of the developing embryo is limited
[11, 12], and reactive oxygen species (ROS) production is exacerbated as the expression
and activities of major ROS scavenging enzymes including superoxide dismutase and
glutathione peroxidase are decreased during maternal diabetes[13-15]. In addition,
maternal hyperglycemia diminishes the level of an important intracellular antioxidant,
glutathione (GSH) [16, 17], which places the developing embryo in an extremely
vulnerable state to oxidative stress.
N-Acetylcysteine (NAC) is a thiol-containing antioxidant agent and can cross the
placenta [18]. The main biological effect of NAC as a precursor of cysteine is to
replenishing cellular GSH levels and to preserve the thiol redox status. Additionally,
NAC also reacts with hydroxyl radical (˙OH), nitrogen dioxide (˙NO2) and thiol radicals
to reduce oxidative stress [19]. Furthermore, NAC treatment in vitro and in ovo
diminishes high glucose-induced developmental defects in mouse and chicken embryos
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[10, 20]. In the present study, we hypothesized that NAC treatment in diabetic mice
during gestation diminishes ROS production and prevents the development of CHDs in
their offspring. To test this hypothesis, a pregestational diabetes mouse model was
established to closely simulate CHDs in patients with pregestational diabetes. We
demonstrated that NAC treatment in pregestational diabetic mice decreased ROS levels
and improved cell proliferation during embryonic heart development, and prevented
CHDs in the offspring of diabetic mice.

2.3 METHODS
2.3.1 Animals
C57BL/6 wild type mice were purchased from Jackson Laboratory (Bar Harbor,
Maine). A breeding program was implemented to generate fetal and postnatal mice.
Animals in this study were handled in accordance with the Guide for the Care and Use of
Laboratory Animals, published by the U.S. National Institutes of Health (NIH publ. no.
85–23, revised 1996). Use of animals was approved by the Animal Use Subcommittee at
the University of Western Ontario, Canada.

2.3.2 Induction of Diabetes Mellitus and N-Acetylcysteine Treatment
Eight week old C57BL/6 female mice were treated with streptozotocin (STZ, 80
mg/kg body weight, IP, Sigma, Canada) for 3 consecutive days. STZ was dissolved in
sodium citrate (pH 4.0) and mice treated with sodium citrate were served as controls.
Non-fasting blood glucose levels were determined one week after STZ injection using a
glucose meter (OneTouch Ultra2, LifeScan, Canada, Burnaby, BC, Canada). Mice with
blood glucose levels higher than 11 mmol/l were bred to normal adult males. Mating was
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verified by observation of a vaginal plug, which was counted as day E0.5 of pregnancy.
A subset of control and diabetic mice received 4 mg/ml N-Acetylcysteine (NAC, 1 g/kg
body weight/day) in drinking water [21] from E0.5 to the end of gestation or harvesting
of the embryos. Non-fasting blood glucose levels were monitored in all groups during
gestation. Water and food intake of pregnant mice was measured and normalized to body
weight.

2.3.3 Histological Analysis
Heart morphology was analyzed in postnatal day 0 (P0) mice and cell
proliferation was analyzed by phospho-histone H3 (pHH3) staining in E12.5 hearts.
Briefly, the mouse thorax was fixed in 4% paraformaldehyde overnight, dehydrated in
ethanol, embedded in paraffin and serially sectioned into 5-µm sections. Heart sections
were stained with hematoxylin/eosin (H/E) and images were captured using a light
microscope (Observer D1, Zeiss, Germany). Images were taken on every 25 µm of the
heart and the three-dimensional visualization of heart structures was reconstructed using
AMIRA® program (FEI, Hillsboro, OR, USA). To analyze cell proliferation and
apoptosis, heart sections were immunostained using anti-pHH3 (phospho S10) antibody
(1:500, Abcam, Toronto, ON, Canada) and anti-cleaved caspase-3 antibody (1:300, Cell
Signaling), respectively, followed by incubation with biotinylated goat anti-rabbit IgG
(1:500, Vector Laboratories, Burlingame, CA, USA). Signals were visualized by 3-3’diaminobenzidine tetrahydrochloride (Sigma-Aldrich Chemie, St. Louis, MO, USA).
Counterstaining was performed with modified Mayer’s hematoxylin (Thermo Scientific,
Waltham, MA, USA). The number of pHH3+ cells from at least 3 individual heart
sections per sample was quantified and normalized to areas of the myocardium.
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2.3.4 Analysis of Superoxide Levels
Embryonic heart tissues were harvested at E12.5 in all four groups. Frozen
samples were cut into 10-µm sections using a cryostat (CM1950, Leica, Germany).
Superoxide levels were assessed by incubation of heart sections with 2 µM
dihydroethidium (DHE) (Invitrogen Life Technologies, Burlington, ON, Canada) for 30
minutes in a humidified and light protected chamber in room air at 37 °C [22]. DHE
fluorescence signals were detected using a fluorescence microscope (Observer D1, Zeiss,
Germany). For analysis of superoxide levels, 5–8 images of each heart sample were
captured using fixed exposure time for all groups. The intensity of fluorescence signals
per myocardial area was quantified using AxioVision software. A limitation of this assay
is that the oxygen level was not adjusted to that of the embryonic hearts in vivo [23].

2.3.5 Real-time RT-PCR Analysis
Total RNA was extracted from individual E11.5 fetal hearts using RNeasy Mini
kit (Qiagen, Burlington, ON, Canada) as per manufacturer’s instructions. One hundred
nanograms of total RNA were used to synthesize cDNA using M-MLV reverse
transcriptase. Real-time PCR was conducted using EvaGreen qPCR MasterMix (Applied
Biological Materials, Vancouver, BC, Canada). Specific primers were designed for
Nkx2.5, Gata4, Gata5, Tbx5, Tgf-β1, Vegf-a, Mef2c, cyclin D1 and Bmp4 (Table 2.1).
Samples were amplified for 35 cycles using Eppendorf Realplex (Eppendorf, Hamburg,
Germany). Values were normalized with 28S ribosomal RNA. The mRNA levels in
relation to 28S rRNA were determined using a comparative CT method [24].
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Table 2.1. Primer sequences for real-time PCR analysis
Gene

Accession No.

Product Size

Primer Sequence (5′→3′)

Nkx2.5

NM_008700.2

162

F: GACAGCGGCAGGACCAGACT
R: CGTTGTAGCCATAGGCATTG

Vegfa

NM_001025257.3

194

F: GATTGAGACCCTGGTGGACAT
R: TCTCCTATGTGCTGGCTTTGG

Gata4

NM_008092.3

134

F: GCCTGCGATGTCTGAGTGAC
R: CACTATGGGCACAGCAGCTC

Gata5

NM_008093.2

167

F: ACCCCACAACCTACCCAGCA
R: GCCCTCACCAGGGAACTCCT

Bmp4

NM_007554.2

250

F: GTTATGAAGCCCCCAGCAGA
R: CCCAATCTCCACTCCCTTGA

Tbx5

NM_011537.3

103

F: AGGAGCACAGTGAGGCACAA
R: GGGCCAGAGACACCATTCTC

Tgf-β1

NM_011577.1

139

F: GCCCGAAGCGGACTACTATG
R: CACTGCTTCCCGAATGTCTG

28S

NR_003279.1

178

F: GGGCCACTTTTGGTAAGCAG
R: TTGATTCGGCAGGTGAGTTG

Cyclin D1

NM_007631.2

135

F: CTGACACCAATCTCCTCAACG
R: CTCACAGACCTCCAGCATCCA

Mef2c

NM_001170537.1

405

F: CACCGAGTACAACGAGCCGCA
R: CTGGTGCCTGCACCGGATGTC
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2.3.6 Glutathione Levels in Fetal Hearts
Briefly, E14.5 fetal hearts were washed in PBS and snap frozen in liquid nitrogen.
Heart samples were homogenized in 6% sulfosalicylic acid and 1 mM EDTA then
centrifuged at 8,000 g for 5 minutes at 4°C. Total and reduced glutathione were assessed
using a modified ultra-performance liquid chromatography (UPLC) method [25, 26]. Nisoamyl alcohol was added to 50 µL of supernatant fraction of all samples. To determine
total glutathione, thiols were reduced with NaBH4 followed by the addition of HCl to
adjust the pH to approximately 8.0, and then derivatized by the addition of 25 mM
monobromobimane. To determine reduced glutathione, the pH of the sample was raised
to approximately 8.0 with NaOH and the samples were immediately derivatized as
described above. Following derivatization, the pH of all samples was decreased to
approximately 4.0 with glacial acetic acid and 5 µL was injected onto a Kinetex C18
column (50 X 2.1 mm, 1.7 µm particle, Phenomenex, Torrance, CA) which was
maintained at 40°C in a Waters AQUITY UPLCTM H-Class System. The mobile phase
consisted 5% acetonitrile and 95% 5 mM KH2PO4 with 0.1% triethylamine, pH 4.0. The
derivatized glutathione was detected by a Waters ACQUITY UPLC® fluorescence
detector with the excitation set to 390 nm and the emission set to 480 nm.

2.3.7 Statistical Analysis
Data are presented as means ± SEM. Statistical analysis was performed using twoway analysis of variance (ANOVA) followed by Bonferroni post test. The incidence of
congenital malformations was analyzed by Chi-square test. P < 0.05 was considered
statistically significant.
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2.4 RESULTS
2.4.1 Effects of NAC on Maternal Blood Glucose Levels, Litter Size and
Mortality at Birth
One week after STZ injection, female mice with blood glucose levels higher than
11 mM were set up to breed with normal males. Diabetic mice had significantly higher
blood glucose levels at the time of vaginal plugging (E0.5) compared to controls (P <
0.001, Figure 2.1 A). Additionally, time to vaginal plugging that lead to successful
pregnancy was 10 times longer in the diabetic compared to control mice (26.7±6.1 vs.
2.7±0.9 days, P < 0.01), indicating decreased fertility rate in diabetic females. From E0.5
to E18.5 of gestation, blood glucose levels of diabetic mice were progressively increased
but not significantly altered by NAC treatment (Figure 2.1 A). Average litter size of
neonates from diabetic mice at P0 was significantly less than controls (Figure 2.1 B).
Additionally, neonates from diabetic mice had 46% mortality rate at birth (P < 0.001,
Figure 2.1 C). Administration of NAC in diabetic dams improved litter size of the
offspring (P < 0.05) and diminished their mortality at birth to 11.5% (P < 0.001). The
body weight of neonates born to diabetic mice was significantly lower compared to
controls at P0 (P < 0.001, Figure 2.1 D). NAC treatment did not affect body weight of
neonates in control mice, but significantly improved the body weight of the diabetic
offspring (P < 0.001, Figure 2.1 D). Food and water intake was significantly higher in the
diabetic females, which was decreased by NAC treatment (Figure 2.2 A-B).
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Figure 2.1. Blood glucose levels of pregnant mice, litter size, mortality and body
weight of neonates at P0.
A) Non-fasting blood glucose levels before mating (basal), and E0.5 to E18.5 after
pregnancy in STZ-treated and control female mice with and without NAC treatment (n =

Fig.
1 C) Mortality of neonates at birth. The
7-10 mice per group). B) The offspring litter
size.
numbers in brackets indicate the number of death to total. D) Body weight of the
offspring at birth (n = 27-29 per group). *P < 0.001 vs. untreated control, †P < 0.001 vs.
untreated diabetes. Data are means ± SEM.
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Figure 2.2. Water and food consumption in female mice.
A-B) Water and food intake was significantly higher in diabetic females. NAC treatment
decreased food and water intake of diabetic females. Data are means ± SEM. N=12-15
females per group. *P<0.001 vs. untreated control, †P<0.001 vs. untreated diabetic and
control NAC.
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2.4.2 Effects of NAC on Incidence of CHDs in Diabetic Offspring
Pregestational diabetes resulted in 58% CHDs in the offspring at postnatal day 0
(Table 2.2). The majority of the defects were malformations of the septum with 31%
atrial septal defect (ASD, Figure 2.3 B) and 40%, ventricular septal defect (VSD, Figure
2.3 C). In addition, 7% of diabetic offspring showed atrioventricular septal defect
(AVSD, Figure 2.3 D). Defects in the outflow tract included 13% double outlet right
ventricle (DORV, Figure 2.3 G) and 7% transposition of great arteries (TGA, Figure 2.3
I). Furthermore, 5% of diabetic offspring showed tetralogy of fallot (TOF) with
pulmonary stenosis (Figure 2.3 E), overriding aorta and VSD associated with right
ventricle hypertrophy (Figure 2.3 F). Treatment with NAC in diabetic mice during
gestation significantly reduced the incidence of CHDs to 16% (Table 2.2). Specifically,
NAC treatment decreased incident of ASD and VSD to 14% and 12%, respectively. Also,
outflow tract formation and remodeling were improved as the rate of DORV was reduced
to 7% while AVSD, TGA and TOF were fully rescued by NAC treatment in the diabetic
mice (Table 2.2). Craniofacial defects were also observed in diabetic embryos (5%,
Figure 2.4 J). However, none of the controls or NAC treated groups showed any
craniofacial defects.
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Table 2.2. The rate of congenital heart defects in the offspring of diabetic and
control females with and without N-Acetylcysteine (NAC) treatment.
Total

Control

Diabetes

Control NAC Diabetes NAC

N/litters

30/4

62/15

30/4

n

%

n

Normal

30

100 26

Abnormal

0

0

ASD

0

VSD

%

n

43/7

%

n

%

41.9** 27

90

36

83.7††

36

58.1** 3

10

7

16.3††

0

19

30.6** 2

6.7

6

13.9†

0

0

25

40.3** 1

3.3

5

11.6††

AVSD

0

0

4

6.5

0

0

0

0

TGA

0

0

4

6.5

0

0

0

0

DORV

0

0

8

12.9*

0

0

3

6.9

TOF

0

0

3

4.8

0

0

0

0

Data were analyzed by Chi-square test. * P < 0.05, ** P < 0.001 vs. untreated control, †P
< 0.05, ††P < 0.001 vs. untreated diabetes. ASD, atrial septal defect; VSD, ventricular
septal defect; AVSD, atrioventricular septal defect; TGA, transposition of great arteries;
DORV, double outlet right ventricle; TOF, Tetralogy of Fallot.
69

70

Figure 2.3. Congenital defects in the diabetic offspring at P0
(A) A normal heart of control offspring. The offspring of mice with pregestational
diabetes show (B) atrial septal defect (ASD), (C) ventricular septal defect (VSD), (D)
atrioventricular septal defect (AVSD), (E and F) tetralogy of Fallot (TOF). (E)
*pulmonary stenosis (PS), (F) VSD, overriding aorta (OA) marked by an arrow, and RV
hypertrophy (RVH), (G) double outlet right ventricle (DORV), and (I) transposition of
great arteries (TGA). Panels (H) and (I) are 3D-reconstructed images of a normal heart
and a TGA, respectively. In panel (H) the aorta (red) is connected to the right ventricle
(RV) while the pulmonary artery (PA in blue) is connected to LV. This defect is
associated with a VSD. (J) Craniofacial defect in diabetic offspring. RA: right atria, LA:
left atria, LV: left ventricle. Arrows indicate ASD or VSD. Scale bar is 200 µm.
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2.4.3 Effects of NAC on Glutathione and ROS levels in the Fetal Heart
of Diabetic Mice
Fetal glutathione levels were measured in E14.5 hearts. Diabetic offspring has
significant reductions in total glutathione, GSH and GSSG levels compared to nondiabetic controls (P < 0.01, Figure 2.3 A-C). The GSH/total glutathione ratio was lower
while GSSG/total glutathione ratio was higher in fetal hearts from diabetic mice (P <
0.05, Figure 2.3 D and E). NAC treatment completely restored total glutathione and GSH
levels in the offspring of diabetic mice (P < 0.001, Figure 2.3 A and B), leading to higher
GSH/total glutathione ratio and lower GSSG/total glutathione ratio (P < 0.01, Figure 2.4
D-E). NAC treatment in non-diabetic females during gestation had no effect on total
glutathione levels but decreased GSSG levels, and consequently GSH/total glutathione
ratio was increased (P < 0.05, Figure 2.4 D). To examine the effects of NAC on ROS
levels, dihydroethidium (DHE) was employed as a probe to assess superoxide generation
in fetal hearts at E12.5. Elevated DHE fluorescence reading in the fetal heart of diabetic
offspring indicated excess superoxide levels, which was significantly inhibited by NAC
treatment (P < 0.05, Figure 2.4).
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Figure 2.4. Measurement of intracellular glutathione levels in fetal hearts at E14.5
A) Total glutathione levels, B) Reduced glutathione (GSH) levels, C) Oxidized
glutathione (GSSG) levels, D) GSH to total glutathione ratio, and E) GSSG to total
glutathione ratio. Data are means ± SEM, n = 7–9 samples per group. *P < 0.05, **P <
0.001 vs. untreated control, †P < 0.001 vs. untreated diabetes.
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Figure 2.5. Analysis of superoxide in fetal hearts at E12.5 using dihydroethidium
(DHE) as a probe
A) Representative images of DHE staining in the LV myocardium of fetal hearts. B)
Quantification of DHE fluorescence intensity. Data are means ± SEM, n = 5–6
samples per group. *P < 0.05 vs. untreated control, †P < 0.05 vs. untreated diabetes.
Scale bar is 20 µm.
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2.4.4 Effects of NAC on Cell Proliferation and Apoptosis in the
Embryonic Heart from Diabetic mice
Proper cell proliferation and apoptosis are essential for normal embryonic heart
development [27, 28]. Using phosphorylated histone H3 (pHH3) as a marker, we
analyzed cell proliferation in fetal hearts at E12.5 and E14.5, that are important stages of
myocardium growth. The offspring of mice with pregestational diabetes had a
significantly lower number of myocardial proliferating cells at E12.5 and E14.5 (P <
0.05, Figure 2.6 A-C). NAC treatment during gestation showed a trend but not a
significant difference in cell proliferation at E12.5. Notably, this effect was significant at
E14.5 (P < 0.001, Figure 2.6 C). In E12.5 endocardial cushion, cell proliferation was
lower in the offspring of diabetic mice (Figure 2.7 A, B). NAC treatment resulted in
significantly higher cell proliferation in endocardial cushion of control and diabetic mice
(Figure 2.7 B). We also assessed cell apoptosis through immunohistochemical analysis of
cleaved caspase-3 (Figure 2.7 A). Apoptosis in the endocardial cushion at E12.5 was
significantly higher in the offspring of diabetic mice compared to controls (P < 0.05,
Figure 2.7 A, C). NAC treatment had no significant effect on apoptosis in the offspring of
diabetic mice, but increased apoptosis in the endocardial cushion in controls (P < 0.05,
Figure 2.7 C). As a result of lower cell proliferation, myocardial wall thickness was lower
in the offspring of diabetic mice at P0 (P < 0.01, Figure 2.8 A-C), which was rescued by
NAC treatment (P < 0.05, Figure 2.8 A-C).
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Figure 2.6. Cell proliferation in the fetal ventricular myocardium.

(A) Representative histological heart sections immunostained for pHH3. pHH3+ staining
(brown) is localized in the nucleus. (B and C) Quantification of pHH3+ cells in heart
tissue sections, which include the right, left and septal myocardium. Data are means ±
SEM, n = 6–8 per group *P < 0.05 vs. untreated control, †P < 0.001 vs. untreated
diabetes. Scale bar is 50 µm.
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Figure 2.7. Cell proliferation and apoptosis in the endocardial cushion at E12.5
(A) Representative immunohistological staining of pHH3 (nucleus) and cleaved caspase3. (B and C) Quantification of pHH3+ cells (cell proliferation) and cleaved caspase-3+ cells
(apoptosis) in relation to total endocardial cushion cells. *P < 0.05 vs. untreated control,
†P < 0.05 vs. untreated diabetes, **P<0.001 vs. untreated control. Scale bar is 50 µm. N=
6-7 hearts per group.
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Figure 2.8. Myocardial wall thickness at P0.
(A) Representative images of myocardial wall thickness. (B and C) Quantification of
right and left ventricular wall thickness. n = 5-6 per group, *P < 0.01 vs. untreated
control, †P < 0.05 vs. untreated diabetes. Scale bar is 200 µm.
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2.4.5 Effects of NAC on Transcription Factor Expression in Fetal
Hearts from Diabetic Mice
Pregestational diabetes alters gene expression levels in the developing heart [29].
To study the effect of pregestational diabetes and NAC treatment on genes essential for
early heart development, quantitative RT-PCR analysis was performed at E11.5. Our data
showed transcript levels of Gata4 and Gata5 were lower in the embryonic hearts of
diabetic mice at E11.5 (P < 0.05, Figure 2.8 A-B). Since GATA4 and GATA5 regulate
cell proliferation in the fetal heart, we evaluated expression levels of cyclin D1, an
important cell cycle regulator. Our data showed that pregestational diabetes significantly
decreased cyclin D1 mRNA levels in the embryonic heart (P < 0.01). On the contrary,
Vegf-a mRNA levels were increased in the embryonic hearts from diabetic mice (P <
0.05, Figure 2.9 C). These changes were all restored to control levels after NAC
treatment (P < 0.05, Figure 2.9 A-D). However, other cardiac transcription factors
including Nkx2.5, Mef2c and Tbx5 were not significantly altered by maternal diabetes or
NAC treatment (Figure 2.9 E-G). In addition, levels of Bmp4 and Tgf-β1, which
regulates cardiac valve formation, were not significantly altered (Figure 2.9 H-I).
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Figure 2.9. Gene expression levels in fetal hearts at E11.5.
(A-D) The mRNA levels of Gata4, Gata5, Vegf-a and cyclin D1 were significantly
altered in diabetic fetal hearts, which were restored to normal levels by NAC. (E-I)
Neither pregestational maternal diabetes nor NAC treatment affected the mRNA levels of
Tbx5, Nkx2.5, Tgf-β1, Mef2c and Bmp4 in the embryonic hearts by two way ANOVA.
Data are means ± SEM, n = 6-8 hearts per group. *P < 0.05 vs. untreated control, †P <
0.05 vs. untreated diabetes.
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2.5 DISCUSSION
Pregestational diabetes is a major risk factor for CHDs in humans. However, the
molecular mechanisms that lead to the development of CHDs and possible therapeutic
approaches to prevent those defects are still not fully understood. It is generally believed
that oxidative stress plays a major role in the induction of birth defects in diabetic fetus
[12, 16, 30]. Here, we employed a mouse model of pregestational diabetes induced by
STZ and studied the effects of NAC treatment on CHDs in the offspring of diabetic mice.
Our data showed that pregestational diabetes resulted in a high incidence of CHDs and
decreased cell proliferation associated with altered expression levels of Gata4, Gata5 and
Vegf-a. Importantly, GSH levels were decreased while ROS levels were increased in the
fetal heart of pregestational diabetes. Notably, these abnormalities in the fetal heart were
rescued by maternal treatment with NAC. Our study provides new evidence on the
critical role of glutathione in embryonic heart development and suggests that NAC may
have therapeutic potential in preventing CHDs in patients with pregestational diabetes.
To simulate congenital malformations induced by maternal diabetes without
genetic modifications, several experimental approaches have been used, which include
STZ- or alloxan-induced diabetes, and infusion of glucose to induce hyperglycemia.
When diabetes or hyperglycemia is induced at the time of mating or within a few days
after gestation, congenital defects in the central nervous system and skeletal
malformation are observed in the offspring [31, 32]. While congenital heart
malformations have been observed in animal studies of diabetic pregnancy, a spectrum of
defects that can arise has been less well characterized [33-35]. In the present study,
diabetes was induced by STZ in female mice for at least one week before gestation to
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avoid the potential teratogenic effects of STZ on developing embryo. Our results show
that pregestational diabetes induces embryopathy with a wide range of cardiovascular
malformations including ASD, VSD, AVSD, TGA, DORV and TOF. These
malformations of the cardiovascular system mirror congenital defects of neonates born to
females with pregestational diabetes [6]. Thus, our model represents an appropriate
animal model to study CHDs induced by pregestational diabetes.
Diabetes increases ROS production through increased activity of ROS generating
enzymes and decreased activity of antioxidant enzymes [36, 37]. Extensive evidence
have shown the involvement of oxidative stress in diabetic embryopathy [38] and the
importance of glutathione in regulating ROS levels and redox signaling [26]. In the
present study, we demonstrated that ROS levels were significantly higher in the fetal
heart of diabetic offspring. Furthermore, total glutathione, GSH and GSSG levels were
lower in the embryonic heart of diabetic offspring. To replenish GSH levels in the
embryonic heart of diabetic mice, female mice with pregestational diabetes were treated
with NAC, a precursor of cysteine essential for the production of GSH [18, 39, 40].
Notably, treatment with NAC normalized GSH levels and ROS levels in the fetal heart of
diabetic mice. Importantly, NAC treatment also resulted in significantly fewer CHDs
induced by pregestational diabetes. These data suggest an important role of GSH
depletion and excessive ROS production in the development of CHDs. Previous studies
have shown that treatment with NAC in vitro or GSH ethyl ester in vivo reduces gross
embryonic malformation induced by high glucose or maternal diabetes [10, 16].
However, the beneficial effect of glutathione on cardiac development was limited to
outflow tract defects induced by high glucose [20, 34]. The present study further
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demonstrated the beneficial effects of NAC on a wide spectrum of cardiovascular
malformations induced by pregestational diabetes in vivo. Additionally, NAC treatment
reduced water and food intake of diabetic mice. While this phenomenon is also observed
in NAC treated diabetic rats [41] our knowledge of the underlying mechanism is limited.
NAC has been demonstrated to delay the onset of type 1 diabetes in biobreeding rats [42]
and protect against hyperglycemia induced insulin resistance in rats [43]. Although, the
beneficial effects of NAC in diabetic condition are explained by replenishing GSH levels
and depleting oxidative stress [44], further studies are required to examine whether NAC
has an effect on intracellular glucose metabolism or insulin sensitivity in diabetic
condition. It should be noted that NAC treatment did not alter total glutathione levels in
the fetal hearts of control mice. This is not surprising because intracellular GSH levels
are regulated by a feedback inhibition to glutamate-cysteine ligase (GCL), a rate limiting
enzyme in the production of GSH [45]. As such, the exogenous NAC participates in GSH
synthesis only during oxidative stress conditions [39]. In addition, NAC also protects
GSH from oxidation through its antioxidant properties independent of GSH synthesis
[46], leading to an increased GSH/total glutathione ratio in both diabetic or control mice
in the present study.
It is well documented that ROS regulates gene expression, cell proliferation and
apoptosis [47]. In the present study, transcription factors that are critical to embryonic
heart development including Gata4, Gata5 [48, 49] were downregulated in diabetic fetal
hearts at E11.5. However similar to previous studies, Vegf-a mRNA levels were higher in
diabetic fetal hearts [35]. Elevated expression levels of VEGF-A are associated with
CHDs [50, 51]. High VEGF-A levels in fetal hearts inhibit epithelial-to-mesenchymal
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transition (EMT) in the endocardial cushion, which contributes to formation of
atrioventricular septum [52, 53]. Although a causal relationship between altered
expression of Gata4, Gata5, Vegf-a and the development of CHDs in our study cannot be
established, the fact that treatment with NAC restored their expression, improved cell
proliferation via restoring cyclin D1 expression and prevented CHDs in diabetic offspring
suggests that these transcription factors are sensitive to redox regulation and their
alteration may contribute at least in part to cardiac malformation in pregestational
diabetes.
Apoptosis is a highly regulated process and aberrant apoptosis may result in
cardiovascular defects [54, 55]. The present study showed that apoptosis in the
endocardial cushion was higher in diabetic embryos. Additionally, treatment with NAC
resulted in higher apoptosis and induced 10% septal defects in control embryos. These
data are consistent with a role of apoptosis in cardiac malformation [55, 56]. Cell
proliferation was assessed using pHH3 staining, which marks cells undergoing mitosis.
Notably, the number of pHH3+ cells in the endocardial cushion and myocardium was
lower in diabetic embryos, which was rescued by NAC treatment. Cell proliferation in
endocardial cushion was also higher with NAC treatment in the control embryos. Since
NAC treatment did not inhibit apoptosis in diabetic embryos in our study, higher cell
proliferation may represent a major effect of NAC in preventing CHDs in diabetes.
In conclusion, the present study demonstrated that pregestational diabetes in mice induces
a wide spectrum of CHDs similar to humans. Treatment with NAC increases GSH levels,
decreases ROS levels in the fetal heart and prevents the development of CHDs in the
offspring of pregestational diabetes. In women with pregestational diabetes, insulin is the
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primary treatment to achieve good glycemic control [57]. However, insulin treatment is
not sufficient to decrease the risk of CHDs in the diabetic offspring to normal levels [38,
58]. Even with optimal care and planning of diabetic pregnancies, the risk of CHDs in the
offspring of diabetic mothers is not as low as in the offspring of nondiabetic mothers (15%). Further studies are required to investigate whether NAC, an FDA approved drug
either alone or in combination with insulin prevents CHDs in infants of women with
pregestational diabetes.
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3.1 CHAPTER SUMMARY
Hypoplastic coronary artery disease is a congenital coronary artery malformation
associated with a high risk of sudden cardiac death. However, the etiology and
pathogenesis of hypoplastic coronary artery disease remain undefined. Pregestational
diabetes increases reactive oxygen species (ROS) levels and the risk of congenital heart
defects. We hypothesized, that pregestational diabetes induces coronary artery
malformation via ROS signaling. Our data show that pregestational diabetes in mice
induced by streptozotocin significantly increased ROS production and decreased
coronary artery diameter and volume in fetal hearts. Pregestational diabetes also impaired
epicardial epithelial-to-mesenchymal transition (EMT) as shown by analyses of the
epicardium, epicardial derived cells and fate mapping. Additionally, ROS-dependent
hypoxia inducing factor (Hif-1α) and epicardial EMT signaling pathway was examined.
The expression of Hif-1α, Snail1, Slug, basic fibroblast growth factor (bFgf) and
retinaldehyde dehydrogenase (Aldh1a2) were lower while E-cadherin expression was
higher in the fetal heart of diabetic mothers. Notably, these abnormalities were all
rescued by treatment with an antioxidant N-Acetylcysteine (NAC) in diabetic females
during gestation. Ex vivo analysis shows that high glucose inhibited epicardial EMT,
which was reversed by NAC treatment. We conclude that pregestational diabetes in mice
can cause coronary artery malformation via ROS signaling. Our study may provide a
rationale for further clinical studies to investigate whether pregestational diabetes could
cause hypoplastic coronary artery disease in humans.
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3.2 INTRODUCTION
Pregestational diabetes is a risk factor for CHDs in infants [1,2]. Clinical studies
have shown that pregestational diabetes increases the risk of CHDs in the offspring by 3–
5 fold compared to non-diabetic pregnancies [1-3]. To date, analysis of congenital heart
malformation in the newborn is mainly restricted to major cardiac structures, which
include aorta, pulmonary artery, atrioventricular septum, cardiac valves and the
myocardium, but coronary arteries are not routinely examined [4]. Importantly,
congenital malformation can occur in coronary arteries leading to null coronary artery or
hypoplastic coronary artery disease [5]. While null coronary artery is embryonically
lethal, hypoplastic coronary artery disease is a rare congenital coronary abnormality
defined by malformation of one or more major branches of the coronary arteries with a
marked decrease in luminal diameter and length. Hypoplastic coronary artery disease can
be asymptomatic, but is often associated with myocardial infarction and sudden cardiac
death during intense physical activities [6]. However, the etiology and pathogenesis of
hypoplastic coronary artery disease remain undefined. Furthermore, it is not known if
pregestational diabetes results in coronary artery malformation in the offspring. Isolated
cases of congenital coronary artery abnormalities have been identified in infants by
autopsy. However, whether the mothers of these patients had pregestational diabetes was
not disclosed in these reports [7,8]. A large multicenter case-control study showed a
significant association between pregestational diabetes and a wide range of CHDs [1].
Since coronary arteries were not routinely examined, defects of coronary arteries were
not reported in this study. Notably, a recent population-based study reported cases of

93

coronary artery anomaly born from mothers with obesity. However, patients with
established diabetes were excluded from this study [9].
Coronary arteries are developed from several sources of progenitors, which include
endothelial cells of sinus venosus, proepicardial organ and the endocardium [10-12]. The
current understanding is that cells from the proepicardial organ migrate toward the
myocardium and form the epicardium. Concurrent with formation of the epicardium, some
epicardial cells undergo epithelial-to-mesenchymal transition (EMT), migrate to the
subepicardial space and myocardium and become epicardial derived cells (EPDCs).
Simultaneously, a sub-population of endothelial cells of the sinus venosus also migrates to
the subepicardial space, forming subepicardial endothelial progenitors [11]. When resident
in the myocardium, the EPDCs give rise to vascular smooth muscle cells and fibroblasts
[13] while subepicardial endothelial progenitors give rise to coronary endothelial cells [14].
Together, EPDCs and subepicardial endothelial cells contribute to the development of
coronary arteries with a minor contribution from the endocardium.
Epicardial EMT is regulated by several epicardial transcription factors and
myocardial induced signalling molecules [15]. An important factor in vasculogenesis and
heart development is hypoxia inducible factor (HIF-1α) [16], which regulates many
downstream target genes, including Wilms tumour-1 (Wt1), a critical transcription factor
expressed in epicardial progenitors and EPDCs [17,18]. Studies have shown that Wt1
directs epicardial progenitors to become smooth muscle cells and fibroblasts, and form
coronary arteries [19]. Pregestational diabetes increases reactive oxygen species (ROS)
production [20,21] and downregulates HIF-1α expression in embryos [22]. We have
shown that treatment with an antioxidant N-Acetylcysteine (NAC) increases reduced
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glutathione (GSH) levels and decreases ROS production in the fetal hearts of diabetic
offspring [20]. The present study was designed to test the hypothesis that pregestational
diabetes impairs epicardial EMT and induces coronary artery malformation in the
offspring. We further hypothesized that these abnormalities are mediated by ROS
signaling and can be rescued by NAC treatment in diabetic females during gestation.

3.3 METHODS
3.3.1 Animals
C57BL/6 wild type, Wt1creERT2/+ and Rosa26mTmG mice were purchased from
Jackson Laboratory (Bar Harbor, Maine).

Animals in this study were handled in

accordance with the Guide for the Care and Use of Laboratory Animals, published by the
U.S. National Institutes of Health (NIH publ. no. 85-23, revised 1996). All procedures
involving mouse handling and manipulation were in accordance with the guidelines of
the Canadian Council of Animal Care and approved by the Animal Use Subcommittee at
the University of Western Ontario, Canada.

3.3.2 Induction of Diabetes and NAC Treatment
Eight week old C57BL/6 female mice were induced to diabetes by streptozotocin
(STZ, 80 mg/kg body weight per day, IP) injections for three consecutive days as
described previously [20,23,24]. STZ was dissolved in sodium citrate (pH 4.0) and mice
treated with sodium citrate were served as controls. Non-fasting blood glucose levels
were determined one week after STZ injection using a glucose meter (OneTouch Ultra2;
LifeScan Canada, Burnaby, BC). Mice with blood glucose levels higher than 11 mmol/l
were considered diabetic and bred to normal adult males. Vaginal plugging was
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monitored as a sign of successful mating and the day of vaginal plugging was recorded as
day E0.5 of gestation. A subgroup of control and diabetic mice received 4 mg/ml NAcetylcysteine (NAC, 1 g/kg body weight/day) in drinking water from E0.5 to the end of
gestation or harvesting of the embryos [20].

3.3.3 Fate Mapping Analysis
Fate mapping of Wt1+ lineage was performed using Wt1creERT2/+ (Stock #10912, Jackson
Laboratory) and the double fluorescent Cre reporter line Rosa26mTmG (Stock #7576).
Wt1creERT2/+ is a heterozygous Wt1-/+ mouse, where exon 1 of the Wt1 gene is deleted and
replaced by a CreERT2 sequence under the control of the Wt1 promoter [19]. CreERT2 is
created by fusion of Cre recombinase to a modified human estrogen receptor ligand
binding domain (ERT2) (Figure 3.1). The Rosa26mTmG reporter mice possess loxP sites on
either side of a membrane-targeted tomato (mT) cassette followed by membrane-targeted
green fluorescence protein (GFP, mG) cassette. In the absence of Cre recombinase
activity, mT (red fluorescence) is expressed in all tissues. In the presence of Cre, the mT
cassette is deleted and mG (green fluorescence) is expressed only in the targeted cells.
Female Rosa26mTmG mice were induced to diabetes by STZ (80 mg/kg body weight per
day, IP for 3 days) as described above, and were bred with Wt1creERT2/+;Rosa26mTmG
males. Tamoxifen (50 mg/kg body weight, IP) was injected to diabetic or control
pregnant females at E10.5. Upon tamoxifen administration, Cre is activated in Wt1
expressing cells and induces recombination to express GFP, which is one of the two
fluorescence proteins in the Wt1creERT2/+;Rosa26mTmG offspring. Embryos were harvested
at E14.5. Double transgenic Wt1creERT2/+;Rosa26mTmG embryos were sectioned and
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immunostained for GFP. The Wt1+ derivatives, which are GFP+ cells and structures, were
quantified and compared between diabetic and control mice.

Figure 3.1. Lineage tracing to evaluate derivatives of epicardial Wt1+ cells.
A)

A

schematic

diagram

of

a

breeding

plan

to

generate

offspring

with

RosamTmG;Wt1CreERT2 genotype. B) Red fluorescence protein (RFP) is transcribed in cells
with no Wt1 expression. CreERT2 is transcribed in Wt1 expressing cells. Upon
tamoxifen administration, Cre is expressed and induce recombination at LoxP sites, thus
Wt1 expressing cells and their lineage will express green fluorescence protein (GFP).
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3.3.4 Analysis of Superoxide Production
Embryonic heart tissues were harvested in all four groups at E14.5. Frozen
samples were cut into 10-µm sections using a cryostat (CM1950, Leica). Superoxide
levels were assessed by incubation of heart sections with 2 µM dihydroethidium (DHE)
(Invitrogen Life Technologies) for 30 minutes in a humidified and light protected
chamber at 37 °C [20]. DHE florescence signals were detected using a florescence
microscope (Observer D1, Zeiss). At least 5 images were captured using fixed exposure
time for each heart and the intensity of DHE florescence signals per myocardial area were
quantified using AxioVision software (Zeiss, Germany).

3.3.5 Immunohistochemistry Analysis
Formation of coronary artery branches was studied at E16.5 and P0 when the
coronary arteries are formed. Immunohistochemical analysis was performed to study
formation of coronary vasculature and their precursors. In brief, the thoraxs of mice were
harvested and processed in 4% paraformaldehyde overnight, dehydrated in ethanol,
embedded in paraffin medium and sectioned transversely to 5 µm sections. Prior to
immunostaining, antigen retrieval was performed in citric acid buffer (0.01 M, pH 6.0)
for 12 minutes at 94 °C using a microwave oven (BP-111, Microwave Research &
Applications, Carol Stream, Illinois). Samples were incubated with primary antibody
overnight: anti-α-smooth muscle actin (1:3000, Sigma-Aldrich, Toronto, ON, Canada),
biotinylated griffonia simplicifolia lectin-1 (1:250, Vector Laboratories, Burlington, ON,
Canada), anti-Wilm’s tumor-1 (1:300, Calbiochem, Etobicoke, ON, Canada), anti-Ecadherin (1:200, Santa Cruz biotechnology, Santa Cruz, CA, USA), anti-GFP (1:1000,
Abcam, Toronto, ON, Canada), anti-phospho-histone H3 (pHH3, 1:500, Abcam, Toronto,
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ON, Canada) and anti-cleaved caspase-3 (1:800, Cell Signaling, Danvers, MA, USA)
followed by one of the following secondary antibodies (Vector Laboratories, Burlington,
ON, Canada) for an hour: biotinylated goat anti-rabbit IgG (1:500), biotinylated goat antimouse IgG (1:500) or biotinylated donkey anti-goat IgG (1:500). Signals were amplified
by incubation with the ABC reagent (Vector Laboratories, Burlington, ON, Canada) and
visualized using 3-3’di-aminobenzidine tetrahydrochloride (Sigma-Aldrich, Toronto, ON,
Canada). Heart sections were counterstained with hematoxylin (Thermo Scientific,
Waltham, MA USA) and images were captured using a light microscope (Observer D1,
Zeiss, Germany). To visualize and analyze coronary artery volume, images of every 25
µm heart sections immunostained with α-smooth muscle actin were captured and
imported to AMIRA® program for three-dimensional reconstructions [20]. Coronary
arteries and the myocardium wall thickness were labeled individually. Using analytical
tools of AMIRA, pixels were converted to volume (µl) and a ratio of coronary artery
volume to myocardial volume was obtained.

3.3.6 Ex vivo Heart Explant Culture
Epicardial cells of E12.5 hearts undergo epithelial to mesenchymal transition
(EMT) when they are cultured on collagen gel. To determine whether hyperglycemia
impairs EMT, the ventricles of E12.5 embryos from control dams were harvested and
cultured on collagen gel. Collagen (1 mg/ml, type I collagen of rat’s tail, BD Bioscience)
was prepared in M199 media (M5017, Sigma), which contained 5 mM D-glucose or in
M199 with addition of 25 mM D-glucose, which made the final D-glucose concentration
to be 30 mM. Casted collagen was hydrated by OPTI-MEM media plus 1% fetal bovine
serum (FBS) and insulin-transferrin-selenium (ITS) for 30 minutes at 37 °C. E12.5
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ventricles were explanted and incubated at 37 °C overnight. The following day, 5 or 30
mM D-glucose in M199 media with 10% FBS were added to the heart explants. The
glucose concentration was about 5 mM higher than the average blood glucose of diabetic
dams at E10.5. To inhibit ROS production, heart explant cultures were treated with 0.5
mM NAC. The number of spindle shaped cell outgrowths from the explanted ventricles
was quantified 4 days post culturing. Images were captured using phase contrast
microscope (Zeiss, Germany).

3.3.7 Real-time RT-PCR Analysis
The epicardium is formed at E10.5 and EMT is initiated followed by formation of
the epicardial cell layer. To examine transcript levels that are important for EMT we
harvested hearts from E11.5 embryos. Total RNA was extracted from individual E11.5
embryonic hearts using RNeasy Mini kit (Qiagen, Burlington, ON, Canada) as per
manufacturer’s instructions. cDNA was synthesized from 0.1 µg of total RNA using MMLV reverse transcriptase in 10 µl reactions, which were diluted by 3 times for genes of
interest and 500 times for a housekeeping gene 28S, respectively. Two microliters of
diluted cDNA were used for real-time PCR amplification using EvaGreen qPCR
MasterMix (Applied Biological Materials, Vancouver, BC, Canada). Specific primers
were designed for Hif-1α, Snail1, Slug, bFgf, β-catenin and Aldh1a2 (Table 3.1).
Samples were amplified for 35 cycles using Eppendorf Realplex (Eppendorf, Hamburg,
Germany). The mRNA levels in relation to 28S ribosomal RNA were determined using a
comparative CT method [25].
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3.3.8 Statistical Analysis
Data are presented as means ± SEM. Statistical analysis was performed using
two-way analysis of variance (ANOVA) followed by Bonferroni post test (GraphPad
Prism program, version 5.0). The incidence of malformation was assessed by Chi-square
test. A P value of less than 0.05 was considered statistically signiﬁcant.

101

Table 3.1. Primer sequences for real-time PCR analysis
Gene

Accession No.

Product Size

Primer Sequence (5ʹ′→ 3ʹ′)

Aldh1a2

NM_009022.4

219

F: GGCAGCAATCGCTTCTCACA
R: CAGCACTGGCCTTGGTTGAA

bFgf

NM_008006.2

174

F: CAAGGGAGTGTGTGCCAACC
R: TGCCCAGTTCGTTTCAGTGC

Ctnnb1

NM_001165902.1 178

F: AGCTTCCTTTTTGGAAAGCTG
R: CTTGGCTGAACCATCACAGAT

Snail1

NM_011427.2

114

F: CACACGCTGCCTTGTGTCT
R: GGTCAGCAAAAGCACGGTT

Slug

NM_011415.2

161

F: CAACGCCTCCAAGAAGCCCA
R: GAGCTGCCGACGATGTCCAT

Hif-1α

NM_010137.3

159

F: CTTGGACGCTCTGCCTATGA
R: AGGTTGCGGGGGTTGTAGAT
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3.4 RESULTS
3.4.1 Pregestational Diabetes Increases ROS Levels in Fetal Hearts
To assess ROS production, dihydroethidium (DHE) was employed as a probe to
detect superoxide generation in the fetal heart. A significant increase in DHE
fluorescence reading in the E14.5 hearts of the offspring of diabetic mice indicated excess
superoxide levels (Figure 3.2 A-B). Notably, treatment with an antioxidant NAC in
drinking water in the diabetic dams during gestation significantly inhibited superoxide
generation in the fetal hearts of diabetic mice (Figure 3.2 A-B). These data suggest that
pregestational diabetes increases ROS levels in the fetal heart, which are effectively
inhibited by NAC treatment.

3.4.2 Coronary Artery Malformation in Fetal Hearts from
Pregestational Diabetes
A critical period for coronary artery development is from E9.5 to E14.5 in mice.
To examine the effect of pregestational diabetes on coronary artery formation, adult
female mice were induced to diabetes by STZ and their non-fasting blood glucose levels
were determined during gestation. Our data show that blood glucose levels in diabetic
females were significantly higher than normal controls (P<0.001, Table 3.2). NAC
treatment did not significantly alter blood glucose levels in the diabetic and normal dams
(Table 3.2).
Formation of coronary artery and capillaries was evaluated following
immunostaining of α-smooth muscle actin and lectin-1, respectively. Offspring ofdiabetic
mothers show lower left and right coronary artery diameter and abundance at P0
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Figure 3.2. Reactive oxygen species (ROS) production assessed by dihydroethidium
(DHE) fluorescence in fetal hearts at E14.5
A) Representative images of DHE red fluorescence in the LV myocardium. B)
Quantification of DHE fluorescence per myocardial area. N=5 fetal hearts from 2 to 3
litters per group. *P<0.05 vs. untreated control, †P<0.01 vs. untreated diabetes. Scale bar
20 µm.	
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Table 3.2. Non-fasting blood glucose levels (mM) during gestation in mice

Control

Diabetes

Control+NAC

Diabetes+NAC

8

10

8

10

At E0.5

6.9 ± 0.3

17.2 ± 1.6 *

7.5 ± 0.3

14.9 ± 1.0 *

At E10.5

8.6 ± 0.5

24.2 ± 2.2 *

8.9 ± 0.5

22.0 ± 1.4 *

Pregnant mice (n)

Data are mean ± SEM. *P<0.05 vs. respective controls. Fetuses and neonates from these
dams were used for histological, immunostaining, ROS and real-time PCR analysis, and
ex vivo heart cultures.

(Figure 3.3 A-B) and at E16.5 (Figure 3.4 A-B). Additionally, coronary arteries in
offspring of diabetic mice had lower numbers of smooth muscle cells surrounding the
vessels (Figure 3.3 C) and lower capillary abundance at P0 (Figure 3.3 D). Impaired
coronary artery development is illustrated in three-dimensional reconstructions of
coronary arteries, which demonstrate smaller arteries with less arborization in offspring
of diabetic mice at E16.5 and P0 (Figure 3.5 A). The impaired coronary artery
development was not simply due to changes in myocardial volume as the ratio of total
coronary artery volume to myocardial volume was lower in the offspring of diabetic mice
at P0 and E16.5 (Fig. 3.5 B-C). The incidence of coronary artery malformation was 46%
(see Table 3.3). To study the role of ROS in coronary artery malformation, diabetic and
control dams were treated with an antioxidant NAC in their drinking water during
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Figure 3.3. Malformation of coronary vasculature in the offspring of diabetic mice
restored by NAC treatment at P0.
Smooth muscle and endothelial cells were marked by α-smooth muscle actin (A-C) and
lectin-1 (D) immunostaining (brown), respectively. A: Representative images of the left
main coronary artery branch at the aortic root. B: Representative images of coronary
artery branches in the myocardium. Arrows are pointed to coronary vessels. C: Coronary
artery vessels in the myocardium. D: Capillaries in the myocardium. E and F: Diameters
of the left and right coronary arteries at the aortic root (n=12-15 hearts per group). G:
Coronary artery abundance per mm2 myocardium (n=7-10 hearts per group). H: Capillary
density per mm2 myocardium (n=5 hearts per group). Data were collected from 3 to 5
litters per group. *P<0.01 vs. untreated control, †P<0.01 vs. untreated diabetes. AO,
aorta; RV, right ventricle; LV, left ventricle; NAC, N-Acetylcysteine. Scale bars are 50
µm in A, C, D and 400 µm in B.

107

108

Figure 3.4. Malformation of coronary artery vasculature in the fetal heart of
diabetic mice restored by NAC treatment at E16.5
A) Representative image of left coronary artery at the aortic root. B) Representative
image of coronary artery branches in the ventricular myocardium. C) Panel C is zoom-up
images of the boxed areas in B to demonstrate differences in vessel size. D) and E)
Quantification of left and right coronary artery diameter. F) Quantification of coronary
artery abundance. N=7-8 samples per group. *P<0.05 vs. untreated control, †P<0.01 vs.
untreated diabetes.
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Figure 3.5. Analysis of three-dimensional (3D) reconstructions of coronary artery
tree demonstrates reduced coronary artery volume in the offspring of diabetic mice
is restored by NAC treatment at E16.5 and P0
A) Illustrations of 3D reconstructions of coronary arteries. B and C) Quantification of the
total coronary artery volume normalized to myocardial volume at E16.5 and P0,
respectively. N=5 hearts from 3 litters per group. * P<0.05 vs. untreated control, †P<0.01
vs. untreated diabetes. RV, right ventricle; LV, left ventricle; NAC, N-Acetylcysteine.
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gestation. Notably, abnormalities in coronary artery and capillary development in the
diabetic offspring were rescued by NAC treatment (Figure 3.3, Figure 3.4, and Figure 3.
5). NAC treatment also significantly rescued the incidence of coronary artery
malformation in the offspring of diabetic mice to 6% (P<0.01, Table 3.3).

3.4.3 Pregestational Diabetes Impairs Epicardial EMT in Fetal Hearts
To gain a better understanding of cellular and molecular events that caused
coronary artery malformation in the offspring of diabetic mice, proepicardial organ and
the epicardium were studied during embryogenesis using presence of Wt1 as a marker.
Our data show that pregestational diabetes did not alter the number of Wt1+ cells in the
proepicardial organ at E9.5 (Figure 3.6). However, the epicardium in the embryonic heart
of diabetic mice formed a sparse and loosely attached cell layer to the myocardium with
significant reductions in the number of Wt1+ epicardial and subepicardial cells at E12.5
(Figure 3.7 A, D and E). Impaired Wt1 expression in fetal hearts of diabetic mothers was
persistent at E14.5, as evidenced by a lower number of Wt1+ cells in the epicardial cell
layer and in the compact myocardium (Figure 3.7 B, F and G). Concurrent with lower in
the number of epicardial Wt1+ cells, the number of E-cadherin positive epicardial cells
was higher in fetal hearts of diabetic mothers at E12.5 (Figure 3.7 C, H). Notably, NAC
treatment during gestation reduced epicardial E-cadherin expression and restored the
number of Wt1+ cells in the epicardium, subepicardium and myocardium in fetal hearts
(Figure 3.7 A-H).
To directly evaluate the derivatives of epicardial Wt1+ cells, fate mapping analysis
was performed using RosamTmG female mice, which were induced to have diabetes by
STZ and then bred to tamoxifen inducible Wt1CreERT2/+;RosamTmG males. Following
112

tamoxifen treatment in the female mice at E10.5, Wt1+ derivatives including coronary
vessels were observed in the hearts of Wt1CreERT2/+;RosamTmG embryos at E14.5 (Figure
3.7 I). In agreement with our hypothesis, pregestational diabetes diminished Wt1+ lineage
and coronary vessels in the hearts of Wt1CreERT2/+;RosamTmG embryos (Figure 3.7 I-K).

Table 3.3. Incidence of coronary artery malformation (CAM) and congenital heart
defects (CHDs) in fetuses from E16.5 to E18.5
Control

Diabetes

Control+NAC

Diabetes+NAC

3

4

3

4

CAM/total fetuses (n/N)

0/26

13/28*

0/25

2/34 †

CHDs/total fetuses (n/N)

0/26

17/28*

0/25

2/34 †

CHDs+CAM/total fetuses

0/26

11/28*

0/25

1/34 †

CAM (%)

0

46

0

6

CHDs (%)

0

61

0

6

CHDs+CAM (%)

0

39

0

3

Litters (n)

(n/N)

CHDs include ventricular septal defects, atrioventricular septal defects, transposition of
great arteries, and double outlet right ventricle. *P<0.001 vs. control; †P<0.001 vs.
diabetes by Chi-square analysis.
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Figure 3.6. Wt1+ cells in the proepicardial organ (PEO) at E9.5.
A) Representative images of PEO of control and diabetic offspring. B) Quantification of
Wt1+ cells to total number of cells in the PEO. N=6 samples per group. There was no
statistical significance in the number of Wt1+ cells in the PEO between control and
diabetic offspring.
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Figure 3.7. Analysis of the epicardium and fate mapping of Wt1+ lineage in hearts of
diabetic offspring.

A and B) Representative heart sections of Wt1 immunostaining at E12.5 and E14.5,
respectively. Arrows point to the epicardium in A and arrow heads point to Wt1+ cells in
the subepicardium and myocardium in A & B, respectively. C) Representative heart
sections of E-cadherin immunostaining at E12.5. Arrow heads indicate E-cadherin+
epicardial cells. D and E) Quantification of Wt1+ epicardial and subepicardial cell
numbers, respectively. F and G) Quantification of Wt1+ cells in the epicardium and
myocardium, respectively. H) Quantification of E-cadherin+ cells to total epicardial cell
ratio (%). I-K: Fate mapping of Wt1+ lineage. I) Representative images of GFP staining
in Wt1creERT2/+;RosamTmG heart sections of control and diabetic offspring at E14.5. Brown
color marks cells and vessels derived from Wt1+ lineage. J and K) Quantification of cells
and vessels derived from Wt1+ lineage in the myocardium, respectively. N=5-6 hearts
from 3 litters per group. *P<0.01 vs. control or untreated control, †P<0.01 vs. diabetes or
untreated diabetes. Scale bars: 30 µm.
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3.4.4 ROS-dependent Downregulation of HIF-1α Signaling in Diabetic
Fetal Hearts
To further understand ROS signalling in epicardial EMT, the expression of Hif1α, a master regulator of vasculogenesis and epicardial EMT [26], and its downstream
signalling molecules essential for coronary development were evaluated. The expression
of Hif-1α was significantly lower in E11.5 fetal hearts of diabetic dams (Figure 3.8 A).
Additionally, mRNA levels of Snail1 and Slug, which are key regulators of EMT, were
significantly lower in fetal hearts of diabetic dams (Figure 3.8 B and C). Furthermore,
retinoic acid signaling may be impaired in the fetal hearts of diabetic dams as evidenced
by lower mRNA levels of Aldh1a2, which encodes the rate-limiting retinoic acid
synthesis enzyme, retinaldehyde dehydrogenase 2 (RALDH2) [27], and its downstream
target bFGF (Figure 3.8 D and E). Notably, these differences in the expression of Hif-1α,
Snail1, Slug, Aldh1a2, and bFGF were restored in the hearts of offspring of diabetic
females by NAC treatment (Figure 3.8 A-E). However, β-catenin mRNA levels that are
essential for coronary artery formation [50] were not significantly altered by
pregestational diabetes or by NAC treatment (Figure 3.8 F).

3.4.5 High Glucose Impairs Epicardial EMT ex vivo
To investigate whether hyperglycemia impairs epicardial EMT in fetal hearts of
diabetic mothers, E12.5 hearts were cultured on collagen gel in both high glucose (30
mM) and normal glucose (5 mM) conditions for 4 days (Figure 3.9 A). The number of
spindle shaped cells, which are epicardial cells, which have undergone EMT was
quantified. Our data show that the number of spindle shaped cells was significantly lower
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in high glucose compared to normal glucose cultures. The response was restored by NAC
(0.5 mM) treatment (Fig. 3.9 A and B).

3.4.6 Pregestational Diabetes Diminishes Epicardial Cell Proliferation
in Fetal Hearts
To assess the effect of pregestational diabetes on epicardial cell proliferation,
immunostaining for pHH3, a marker of mitotic cells, was performed in fetal hearts. Our
results show that the number of pHH3+ epicardial cells was significantly lower in fetal
hearts of diabetic dams at E12.5 and E14.5 (Figure 3.10 A-D). Interestingly, treatment
with NAC in diabetic dams completely restored epicardial cell proliferation at both time
points (Figure 3.10 C and D). Assessment of the apoptotic epicardial cells in E12.5 hearts
using immunostaining for cleaved caspase-3 show no significant difference between the
control (0.37±0.16%) and diabetic groups (0.33±0.12%, n=8-10 hearts per group).
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Figure 3.8. Gene expression of HIF-1α and its downstream targets critical to
epicardial EMT in E11.5 hearts
mRNA levels were analyzed by real-time PCR. A) HIF-1α. B) Snail1. C) Slug. D)
Aldh1a2. E) bFGF. F) β-Catinin. *P<0.05, **P<0.01 vs. untreated control, †P<0.05,
††P<0.01 vs. untreated diabetes. N=7-9 hearts from 3 to 4 litters per group.
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Figure 3.9. High glucose inhibits EMT ex vivo.
A) Representative images of ex vivo E12.5 heart explant culture. Dashed line shows the
border of migrated cells. B) Quantification of the number of spindle shaped cells, which
are cells that have undergone EMT. Scale bar: 50 µm. *P<0.01 vs. untreated control (5
mM D-glucose), †P<0.01 vs. untreated high glucose (30 mM). N=10-12 hearts per group
from 4 litters.
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Figure 3.10. Reduced rate of epicardial cell proliferation in the fetal heart of
diabetic mice restored by NAC treatment at E12.5 and E14.5.
A and B) Representative images of immunostaining of phospho-histone H3 (pHH3,
brown) in E12.5 and E14.5 hearts, respectively. C and D) Quantification of pHH3+
epicardial cells per millimeter epicardium. N=6-8 hearts from 3 litters per group. Scale
bar: 20 µm. *P<0.05 vs. untreated control, †P<0.01 vs. untreated diabetes.
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3.5 DISCUSSION
To our knowledge, the present study demonstrated for the first time that
pregestational diabetes impairs development of coronary artery vasculature in fetal hearts
in an animal model. We further demonstrated that pregestational diabetes increases ROS
production, diminishes HIF-1α and Wt1 expression, and decreases Snail/Slug and
RALDH2/bFGF signalling pathways leading to disruption of epicardial EMT and
malformation of fetal coronary arteries (for a schematic diagram of the proposed
pathway, see Figure 3.11). Notably, inhibition of ROS production by antioxidant NAC
restores epicardial EMT and prevents malformation of coronary arteries in the fetal heart
of pregestational diabetes. Our study suggests a critical role of ROS signalling in
coronary artery malformation during pregestational diabetes.
The embryonic epicardium is a major contributor to coronary artery development
[28,29]. In this regard, cells from the epicardium undergo EMT and become EPDCs,
which then differentiate into vascular smooth muscle cells and cardiac fibroblasts,
leading to formation of coronary vessels. To study if pregestational diabetes affects
epicardial formation, immunohistochemical analysis was performed. Although there were
no significant changes in proepicardial organ progenitor cell numbers, the number of
epicardial cells was lower and the epicardium was detached from the myocardium with
lower in epicardial cell proliferation at E12.5 and E14.5 in embryonic hearts of diabetic
mothers. Epicardial attachment to the myocardium is critical to epicardial cell proliferation
and formation of the epicardium [30]. Our study shows that pregestational diabetes inhibits
epicardial development likely via an interruption of epicardial attachment to the
myocardium and a reduction of epicardial cell proliferation. The number of epicardial cells
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Figure 3.11. Schematic summary of ROS signaling on coronary artery malformation
in the offspring of pregestational diabetes
Pregestational diabetes increases ROS via hyperglycemia and hypoxia. ROS production
inhibits HIF-1α and Wt1 expression in the fetal heart. Downregulation of Wt1 decreases
epicardial EMT and results in coronary artery malformation via inhibition of Snail/Slug
and RALDH2/bFGF pathways. These abnormalities were all prevented by treatment with
an antioxidant NAC in the diabetic dams.
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undergoing apoptosis was low (0.3%) and no significant difference was observed at
E12.5 between control and diabetic offspring. However, whether pregestational diabetes
increases epicardial cell apoptosis in the offspring at other stages of development remains
to be determined.
Epicardial EMT is a critical process in coronary artery development [31]. In the
present study, we demonstrated that pregestational diabetes decreases epicardial EMT.
This is supported by the following experimental data. First of all, the number of Wt1+
cells, which are EPDCs from epicardial EMT, was lower in the subepicardial space and
in the compact myocardium of diabetic offspring. Secondly, high glucose inhibited
epicardial cell outgrowth in cultured heart explants, and thirdly, fate mapping analysis
revealed significantly lower Wt1+ cell lineage in the fetal heart of pregestational diabetes.
The Wt1creERT2 line has been shown to label the epicardium and its derivatives [32]. The
lower Wt1+ lineage in the fetal heart of diabetic offspring is consistent with our
hypothesis that pregestational diabetes impairs epicardial EMT. To our knowledge, this is
the first experimental evidence to show that pregestational diabetes inhibits epicardial
EMT in the fetal heart.
HIF-1α is a transcription factor that promotes vasculogenesis during embryonic
development [33]. To this end, HIF-1α signalling has been shown to regulate epicardial
EMT and EPDC migration into the myocardium, both of which are critical in patterning
the coronary vasculature during early cardiac vasculogenesis [26]. The effects of HIF-1α
are mediated by the expression of factors essential for coronary artery development
including Wt1 [17,34]. Importantly, HIF-1α is also ROS sensitive. While low levels of
ROS increase HIF-1α expression and promote cardiovascular differentiation, high levels
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of ROS may inhibit HIF-1α activity by inhibiting the binding of co-activator p300 to
HIF-1α [35,36]. Furthermore, diabetes via hyperglycemia, increases ROS levels and
decreases the expression and activity of HIF-1α [37,38]. In the present study, ROS levels
were significantly higher while HIF-1α expression and the number of Wt1+ epicardial
cells and EPDCs were lower in the embryonic heart of pregestational diabetes. Notably,
these changes were abrogated by NAC treatment, which reduces ROS levels in the
embryonic heart. Our data show that pregestational diabetes impairs HIF-1α/Wt1
signalling pathway via elevated ROS levels in the fetal heart (Figure 3.11).
Wt1 has been shown to regulate epicardial EMT through the expression of its
downstream targets of Snail1, Slug and RALDH2 [39-41]. In line with our observation of
lower epicardial EMT, we further demonstrated that the expression of Snail1 and Slug
was lower in the embryonic hearts of pregestational diabetes. Retinoic acid feeds into an
essential signalling pathway crucial for epicardial formation, epicardial attachment to the
myocardium, myocardial growth and proliferation, and coronary artery development
[42,43]. bFGF is an important mediator in retinoic acid signalling that promotes
epicardial EMT and vasculogenesis in the embryonic heart. Our results show that the
expression levels of Aldh12a, which encodes RALDH2, and its downstream target bFGF
were lower, suggesting an impaired retinoic acid signalling in the fetal heart of diabetic
mothers.

Thus,

pregestational

diabetes

impairs

both

Wt1/Snail/Slug

and

Wt1/RALHD2/bFGF signalling pathways, which may contribute to decreased epicardial
EMT and malformation of coronary arteries in the fetal heart (Figure 3.11).
Physiological levels of ROS signalling regulates vasculogenesis [44]. While basal
endogenous ROS levels are critical to normal vascular development, excessive ROS
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production during embryogenesis may inhibit vasculogenesis. In this regard, elevated
ROS levels induce vasculopathy in the yolk sac of embryos of diabetic rats [45]. NAC is
a precursor of cysteine and decreases ROS levels via increases in glutathione synthesis
and antioxidant capacity [46]. The present study showed that ROS production was higher
in the fetal heart of pregestational diabetes. Notably, NAC treatment in diabetic females
during gestation diminished ROS levels and restored expression of critical factors
essential for epicardial growth and EMT. Importantly, NAC treatment rescued coronary
artery malformation induced by pregestational diabetes. Our study suggests a critical role
of elevated ROS and its signalling in mediating coronary artery malformation in the
offspring of pregestational diabetic mice. Previous studies have shown that
hyperglycemia or pregestational diabetes induces CHDs, which can be prevented by
antioxidant treatments (Chapter 2), [47-49]. The results are consistent with our recent
findings that elevated ROS levels contribute to the development of CHDs in the offspring
of mice with pregestational diabetes, which are rescued by NAC treatment (Chapter 2).
Thus, NAC may have therapeutic potential in the prevention of congenital heart defects
including coronary artery malformation in patients with pregestational diabetes.
In conclusion, the present study demonstrates that pregestational diabetes impairs
epicardial EMT and coronary artery development in mice. These abnormalities are
associated with increased ROS production and decreased HIF-1α/Wt1 signalling (Figure
3.11). Notably, these abnormalities were all prevented by an antioxidant NAC treatment,
suggesting a key role of ROS signalling in the malformation of coronary arteries in
pregestational diabetes. The coronary artery phenotype observed in the present study
bears resemblance to human hypoplastic coronary artery disease, which has a high risk of
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spontaneous myocardial infarction and sudden cardiac death [6]. Our study suggests that
pregestational diabetes could cause hypoplastic coronary arteries in mice. However,
further clinical studies are required to determine whether pregestational diabetes
increases the incidence of hypoplastic coronary artery disease in humans.
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4.1 CHAPTER SUMMARY
NADPH oxidases (NOX) are a major source of reactive oxygen species (ROS)
production in the heart. ROS signalling regulates gene expression, cell proliferation,
apoptosis and migration. However, the role of NOX in embryonic heart development
remains elusive. We hypothesized that deficiency of Nox2 disrupts endocardial to
mesenchymal transition (EndMT) and results in congenital septal and valvular defects.
Our results show that 34% of Nox2-/- neonates had various congenital heart defects
(CHDs) including atrial septal defects (ASD), ventricular septal defects (VSD),
atrioventricular canal defects (AVCD), and malformation of atrioventricular (AV) and
aortic valves. Notably, Nox2-/- embryonic hearts show abnormal development of the
endocardial cushion as evidenced by reduced rate of cell proliferation and an increased
rate of apoptosis. Additionally, lack of Nox2 disrupted EndMT of cushion explants ex
vivo. Furthermore, treatment with N-Acetylcysteine (NAC) to reduce ROS levels
significantly decreased the number of cells undergoing EndMT in wild type and Nox2-/embryos. Importantly, deficiency of Nox2 reduced cardiac expression of Gata4, Tgfβ2,
Bmp2, Bmp4 and Snail1, which are essential for EndMT and endocardial cushion
development. We conclude that NOX2 is critical to EndMT and embryonic development
of endocardial cushion-derived structures including heart valves and cardiac septum.
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4.2 INTRODUCTION
Congenital heart defects (CHDs) are the most common birth defects in infants
affecting 1-5% of live births [1]. Malformation of septal and valvular structures are
reported in about 40% of patients with CHDs [2]. Cardiac morphogenesis is regulated by
an intricate network of signalling molecules and transcription factors [3]. Advances in
genetic analysis have assisted in identifying genomic factors responsible for
morphological abnormalities in patients with CHDs [4]. Currently, about 20% of CHDs
are attributed to chromosomal abnormalities, single gene mutations or environmental
teratogens. However, the etiology of 80% of CHDs remains unknown [5], indicating our
limited knowledge on factors that regulate cardiac morphogenesis.
Reactive oxygen species (ROS) are an important signalling molecules that
modulate intracellular redox state and gene expression profiles to regulate cell
proliferation, differentiation, apoptosis and migration [6,7]. An imbalance in ROS
production may have adverse effects on fetal development [8,9]. To this end, we (Chapter
2) and others have shown that excessive ROS generation in the embryonic heart alters
gene expression profile and induces a wide range of CHDs [10], suggesting a pivotal role
of ROS production in normal heart development.
A critical process in embryonic heart development is the epithelial to
mesenchymal transition (EMT). The endocardial EMT (EndMT) is initiated at E9.5 in
mice when endocardial cushion swellings are formed in the outflow tract (OFT) and AV
canal regions [11]. With contributions from neural crest cells, endocardial cushions at
OFT form the aorticopulmonary septum and semilunar valves, while endocardial cushion
at AV canal participate in the formation of AV valves and cardiac septum. EndMT is
133

regulated by transcription factors and signalling molecules produced in the adjacent
myocardium and endocardium cushions [12].
NADPH oxidases (NOX) are a family of O2- and H2O2 producing enzymes
expressed in both phagocytic and non-phagocytic cells [13]. The enzyme complex is
composed of NOX proteins, p22phox, p40phox, p47phox, p67phox and Rac GTPase. ROS
production from NOX enzymes by phagocytes plays an important role in killing invading
pathogens. The heart also expresses NOX proteins. A major source of intercellular ROS
production in adult cardiomyocytes and embryonic cardiac stem cells is NOX2 and
NOX4 [14,15]. Mutations of NOX genes result in chronic granulomatous disease (CGD),
a rare disease occurring in 1:200,000-450,000 live births [16]. Notably, atrial septal
defects are also seen in patients with CGD [17], suggesting that mutations of NOX genes
or a lack of NOX-derived ROS production may cause CHDs. However, mechanisms by
which NOX enzymes regulate heart development are not clear. In this study, we
hypothesized that deficiency of Nox2 disrupts EndMT and results in congenital septal and
valvular defects. To test this hypothesis, a Nox2 deficient mouse was employed. Our data
show that Nox2-/- mice have cardiac septal defects and valvular abnormalities.
Furthermore, deficiency of Nox2 impairs EndMT and endocardial cushion development.
Our study supports a critical role of Nox2-derived ROS signaling in promoting EndMT
and embryonic heart development.
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4.3 METHODS
4.3.1 Animals
Nox2-/- and C57Bl/6 mice were purchased from Jackson Laboratory (Bar Harbor,
Maine). Genotype was confirmed by PCR analysis using the following primers: 5'
AAGAGAAACTCCTCTGCTGTGAA

3'

and

5'

GTTCTAATTCCATCAG

AAGCTTATCG 3', provided by Jackson Laboratory. A breeding program was
implemented to harvest fetal and postnatal mice. Animals in this study were handled in
accordance with the Guide for the Care and Use of Laboratory Animals, published by the
U.S. National Institutes of Health (NIH publ. no. 85-23, revised 1996). All procedures
involving mouse handling and manipulation were in accordance with the guidelines of
the Canadian Council of Animal Care and approved by the Animal Use Subcommittee at
the University of Western Ontario, Canada.

4.3.2 Immunohistochemistry Analysis
Heart morphology was analyzed in postnatal day 0 (P0) mice. Briefly, the mouse
thorax was fixed in 4% paraformaldehyde overnight, dehydrated in ethanol, embedded in
paraffin medium and sectioned transversely to 5 µm sections. Prior to immunostaining,
antigen retrieval was performed in citric acid buffer (0.01 M, pH 6.0) for 12 minutes at
94 °C using a microwave oven (BP-111, Microwave Research & Applications, Carol
Stream, Illinois). Samples were incubated with primary antibodies overnight: anti-Ki67
(1:500, Abcam, Toronto, ON, Canada), anti-caspase-3 (1:800, Cell Signaling, Danvers,
MA, USA), anti-Snail1 (1:300, Abcam, Toronto, ON, Canada), or anti-NOX2 antibody
(1:500, BD transduction laboratories, Mississauga, ON, Canada) followed by one of the
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following secondary antibodies (Vector Laboratories, Burlington, ON, Canada) for an
hour: biotinylated goat anti-rabbit IgG (1:500) or biotinylated goat anti-mouse IgG
(1:500). Signals were amplified by incubation with the ABC reagent (Vector
Laboratories, Burlington, ON, Canada) and visualized using 3-3’di-aminobenzidin
tetrahydrochloride (Sigma-Aldrich, Toronto, ON, Canada). Heart sections were
counterstained with hematoxylin (Thermo Scientific, Waltham, MA USA) and images
were captured using a light microscope (Observer D1, Zeiss, Germany). Endocardial
cushion cell density was calculated at E10.5 by quantifying the number of cells in
endocardial cushion per area.

4.3.3 Analysis of Superoxide Levels
Embryonic heart tissues were harvested at E10.5. Frozen samples were cut into 10µm sections using a cryostat (CM1950, Leica, Germany). Superoxide levels were
assessed by incubation of heart sections with 2 µM dihydroethidium (DHE, Invitrogen
Life Technologies, Burlington, Canada) for 30 minutes in a humidified and light
protected chamber in room air at 37°C [18]. DHE fluorescence signals were detected
using a fluorescence microscope (Observer D1, Zeiss, Germany). For analysis of
superoxide levels, 5 images of each heart sample were captured using fixed exposure
time for both groups. The intensity of fluorescence signals per myocardial area was
quantified using AxioVision software. A limitation of this assay is that the oxygen level
was not adjusted to that of the embryonic hearts in vivo [19].
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4.3.4 Real-time RT-PCR Analysis
Total RNA was extracted from E10.5 fetal hearts using RNeasy Mini kit (Qiagen,
Burlington, ON) as per manufacturer’s instructions. cDNA (100 ng) was synthesized
using M-MLV reverse transcriptase. Real-time PCR was conducted using EvaGreen
qPCR MasterMix (Applied Biological Materials, Vancouver, BC). Specific primers were
designed for Nkx2.5, Gata4, Gata5, Tbx5, Bmp2, Bmp4, Tgf-β1, Tgf-β2, Notch1, Snail1
and Mef2c (Table 4.1). Samples were amplified for 35 cycles using Eppendorf Realplex
(Eppendorf, Hamburg, Germany). The mRNA levels in relation to 28S ribosomal RNA
were determined using a comparative CT method .

4.3.5 Ex vivo Endocardial Cushion Explant Culture
EndMT was assessed using endocardial cushion explants ex vivo [20,21].
Collagen (1 mg/ml, type I collagen from rat tail, BD Bioscience, Mississauga, ON,
Canada) was prepared in M199 culture media (M5017, Sigma-Aldrich, Toronto, ON,
Canada). Casted collagen was hydrated by OPTI-MEM media plus 1% of fetal bovine
serum (FBS) and insulin-transferrin-selenium (ITS) for 30 minutes at 37 °C. Hearts were
isolated from E10.5 Nox2-/- and WT embryos. Atria and ventricular chambers were
dissected out and the AV canal was cut open longitudinally and planted on the hydrated
collagen gel with the endocardium facing the gel. Cushion explants were incubated at 37
°C overnight. The following day, M199 media with 10% of FBS were added to the
cushion explants. To inhibit ROS production, heart explant cultures were treated with 5
mM NAC. The number of spindle shaped cells outgrowth from the explanted ventricles
was quantified 4 days post culturing. Images were captured using phase contrast
microscope (Observer D1, Zeiss, Germany).
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4.3.6 Statistical Analysis
Data are presented as means ± SEM. Statistical analysis performed using Student ttest or two-way analysis of variance (ANOVA) followed by Bonferroni corrections
(GraphPad Prism, version 5.0). Survival rate and incidence of congenital malformations
was analyzed by Chi-square test. A P value of less than 0.05 was considered statistically
signiﬁcant.
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Table 4.1. Primer sequences for real-time PCR analysis.
Gene

Accession No.

Product

Primer Sequence (5ʹ′→ 3ʹ′)

Size
Bmp2

NM_007553.3

151

F: CAAACACAAACAGCGGAAGC
R: CAGCAAGGGCAAAAGGACAC

Bmp4

NM_007554.2

250

F: GTTATGAAGCCCCCAGCAGA
R: CCCAATCTCCACTCCCTTGA

Gata4

NM_008092.3

134

F: GCCTGCGATGTCTGAGTGAC
R: CACTATGGGCACAGCAGCTC

Gata5

NM_008093.2

167

F: ACCCCACAACCTACCCAGCA
R: GCCCTCACCAGGGAACTCCT

Mef2c

NM_001170537.1

405

F: CACCGAGTACAACGAGCCGCA
R: CTGGTGCCTGCACCGGATGTC

Nkx2.5

NM_008700.2

162

F: GACAGCGGCAGGACCAGACT
R: CGTTGTAGCCATAGGCATTG

Notch1

NM_008714.3

142

F: CAGCTTGCACAACCAGACAGA
R: TAACGGAGTACGGCCCATGT

Snail1

NM_011427.2

114

F: CACACGCTGCCTTGTGTCT
R: GGTCAGCAAAAGCACGGTT

Tbx5

NM_011537.3

103

F: AGGAGCACAGTGAGGCACAA
R: GGGCCAGAGACACCATTCTC

Tgf-β1

NM_011577.1

139

F: GCCCGAAGCGGACTACTATG
R: CACTGCTTCCCGAATGTCTG

Tgf-β2

NM_009367.3

230

F: CTGTGCAGGAGTGGCTTCAC
R: GCAGGAGATGTGGGGTCTTC

28S

NR_003279.1

178

F: GGGCCACTTTTGGTAAGCAG
R: TTGATTCGGCAGGTGAGTTG

F: Forward, R: Reverse.Primers of Bmp4, Gata4, Gata5, Mef2c, Tbx5, Tgf-β1 and 28S
were also used in Chapter 2.
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4.4 RESULTS
4.4.1 Reduced Viability, Litter Size and Body Weight in Nox2-/Neonates
Mortality at birth in Nox2-/- mice was about 4 fold higher than WT neonates (16%
vs. 4.6%) with diminishing survival rate during the first three weeks of life (P<0.001,
Figure 4.1A). Litter size in Nox2-/- mice was smaller (P<0.05, Figure 4.1B), and their
body weight at birth was significantly lower compared to WT controls (P<0.05, Figure
4.1C). A significantly lower in body size or growth retardation was observed in 24% of
Nox2-/- embryos collected at E10.5-12.5 (Table 4.2, Figure 4.1D). Some of the embryos
may undergo in utero absorption, as suggested by lower litter size in Nox2-/- mice.

4.4.2 Septal and Valve Defects in Nox2-/- Mice
Histological analysis of Nox2-/- hearts at P0 showed that 34% of Nox2-/- mice were
born with various types of CHDs, which included 18% atrial septal defects (ASD) and
18% ventricular septal defects (VSD, Table 4.3, Figure 4.2A). Additionally, severe cases
of septal malformation in the form of atrioventricular canal defects (AVCD) were
observed in 3.3% of Nox2-/- neonates. Furthermore, 6.6% of Nox2-/- neonates had
bicuspid aortic valves (BAV, Table 4.3, Figure 4.2 A). It should be noted that all cases of
BAV were associated with septal abnormalities. Most Nox2-/- mice had a single ASD or
VSD. However, 2 out of 61 Nox2-/- mice (3.3%) had both ASD and VSD. In addition,
Nox2-/- hearts demonstrated valvular abnormalities. Specifically, the mitral and tricuspid
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Figure 4.1. Survival and growth in Nox2-/- mice.
A) Mortality rate in Nox2-/- mice at birth and during the first three weeks of life compared
to their age matched controls. N=129 in wild type (WT) group and N=112 in Nox2-/group. B) Litter size at birth, N=10 or 13 litters per group. C) Body weight of neonates at
birth, N=28 samples per group. D) Representative images of body size of WT and Nox2-/mice at E10.5. Scale bar is 1 mm. *P<0.05, **P<0.001 vs. WT by Chi-square in A and
unpaired Student t test in B and C.
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Table 4.2. Number and percentage of embryos with growth retardation at E10.512.5.
Number of litters

Growth Retardation
(n/N)

(%)

WT

4

0/29

0

Nox2-/-

4

6/25*

24*

*P<0.01 vs. WT by Chi-square test.

Table 4.3. Incidence of congenital heart defects in Nox2-/- mice at P0.
Wild-type

Nox2-/-

(N=35 from 5 litters)

(N=61 from 12 litters)

N

%

N

%

Normal

35

100

40

65.6**

Abnormal

0

0

21

34.4**

ASD

0

0

11

18*

VSD

0

0

11

18*

AVCD

0

0

2

3.3

BAV

0

0

4

6.6

ASD, atrial septal defect; VSD, ventricular septal defect; AVCD, atrioventricular canal
defect. *P<0.05, **P<0.01 vs. wild-type by Chi-square analysis.
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Figure 4.2. Congenital heart defects in Nox2-/- mice at P0.
A) Representative histological images of normal and abnormal hearts. Nox2-/- mice
demonstrated ASD, AVCD, membranous and muscular (arrows) types of VSD, and
BAV. B) Representative histological images of tricuspid and mitral valves. C)
Representative histological images of aortic and pulmonary valves. D) Quantification of
mitral and tricuspid valve length, E) quantification of mitral and tricuspid valve
thickness. F) Quantification of aortic valve cell density. *P<0.05 vs WT, N= 9-12 per
group, Scale bar in A is 200 µm and in B-C is 100 µm.
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valves were shortener in length (Figure 4.2 B & D) and the distal tip of the mitral valve
was bigger in size in Nox2-/- mice (P<0.05, Figure 4.2 B & E), but there was no
significant difference in the thickness of distal region of tricuspid valves (Figure 4.2 B &
E). Additionally, aortic valves of some Nox2-/- mice had a bulging shape with lower cell
density (P<0.05, Figure 4.2 C & F) while no apparent abnormalities were found in the
pulmonary valves.

4.4.3 NOX2 Expression Pattern and Endocardial Cushion Formation
in Embryonic Heart
To examine the expression pattern of NOX2, immunohistochemical analysis was
performed. NOX2 immunostaining was seen in the atrial and ventricular myocardium at
E10.5 (Figure 4.3 A). Remarkably, NOX2 expression was more robust on the left
ventricular myocardium compared to the right (Figure 4.3 C, E). Importantly, NOX2 was
expressed in the myocardium covering endocardial cushions at the OFT and AV canal,
suggesting their possible role in regulation of endocardial cushion development (Figure
4.3 D, F). However, the epicardium, endocardium and cells within the endocardial
cushion do not express NOX2 in the WT hearts at E10.5 (Figure 4.3 C-E). As expected,
in Nox2-/- mice, NOX2 protein was not expressed (Figure 4.3 B, G), and the ROS levels
were lower in the myocardium (P<0.05, Figure 4.4). Furthermore, cellular density in
endocardial cushion was significantly lower in Nox2-/- compared to WT hearts at E10.5
(Figure 4.3 G).
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Figure 4.3. Expression of NOX2 in E10.5 hearts.

A) Representative images of NOX2 immunostaining in embryonic heart of WT mice. B)
Loss of NOX2 expression in Nox2-/- mice. C-E) Enlarged from A showing expression of
NOX2 in right and left atrial and ventricular myocardium of WT mice. D &F)
Expression of NOX2 in the myocardial cells covering the endocardial cushion at the AV
canal and OFT of WT mice. G) Lack of NOX2 expression and lower cellular density
were evident in OFT cushions of Nox2-/- hearts. Panels f and g are enlarged images of
boxed area in F and G. Scale bar is 100 µm.
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Figure 4.4. Analysis of superoxide levels in fetal hearts at E10.5 using
dihydroethidium (DHE) as a probe.

A) Representative images of ROS levels in the left venticle myocardium. B)
Quantification of DHE fluorescence intensity. Scale bar is 30 µm. Data are means ±
SEM. N=3 hearts per group. *P<0.01 vs. WT by unpaired Student’s t test.
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4.4.4 EndMT Is Impaired in Nox2-/- Hearts
To investigate the role of NOX2 in endocardial cushion formation, we evaluated
EndMT of endocardial cells in vivo and in vitro. To this end, expression levels of Snail1,
an important marker of EMT [22], were analyzed. Our data show that Snail1 mRNA
levels in the heart at E10.5 as well as the number of Snail1 positive cells in the AV
cushion at E12.5 were lower in Nox2-/- compared to WT embryos (P<0.05, Figure 4.5 A,
C, D). To examine EndMT, the endocardial cushion of E10.5 fetal hearts was cultured on
collagen gel and allowed for cell outgrowth for four days (Figure 4.5 B). The number of
spindle shaped cells, which had undergone EndMT, were quantified. Nox2-/- endocardial
cushion had significantly lower in the number of spindle shaped cells compared to WT
cushions (P<0.05, Figure 4.5 B, E). To lower ROS levels, wild type and Nox2-/endocardial cushions were treated with a ROS quenching agent, N-Acetylcysteine
(NAC). Notably, treatment with NAC diminished EndMT in both WT and Nox2-/endocardial cushion (P<0.001, Figure 4.5 B, E).

4.4.5 Nox2 Deficiency Reduces Expression of Genes Crucial for
EndMT
To further investigate the role Nox2 in regulating EndMT, we examined the
expression of transcription factors and growth factors critical to EndMT and heart
development in 10.5 hearts. Our data show that mRNA levels of Gata4, a transcription
factor important in septal development, were diminished in Nox2-/- mice. As well,
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Figure 4.5. Analysis of endocardial EMT in vivo and in vitro.
A) Representative images of Snail1 expression in the endocardial cushion (EC) at E12.5.
Lower panels are enlarged images of boxed areas in WT and Nox2-/-, respectively. B) EC
ex vivo culture demonstrates EMT in the presence or absence of 5 mM NAC. Dashed line
outlines cell migration border. C) Quantification of Snail1 positive cells in EC (N=4-5
hearts per group). D) Analysis of Snail1 mRNA expression levels at E10.5 fetal hearts
(N=5 hearts per group). E) Quantification of the number of spindle shaped cells (N=4-5
hearts per group). Data are means ± SEM. *P<0.05 vs. untreated WT, **P<0.001 vs.
untreated WT, †P<0.05 vs. untreated Nox2-/-. Scale bars are 100 and 20 µm in A, and 200
µm in B.
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the expression levels of members of TGF-β superfamily, including Tgf-β2, Bmp2 and
Bmp4, which are important regulators of endocardial cushion formation [23], were
significantly lower in Nox2-/- fetal hearts at E10.5 (P<0.05, Figure 4.6 A-D). However,
the expression levels of other cardiac transcription factors including Nkx2.5, Tbx5, Gata5
and Mef2c were not altered in Nox2-/- embryonic hearts (Figure 4.6 E-H). Additionally,
the expression of Tgfβ1 and Notch1 [24-26] was not significantly different in Nox2-/hearts (Figure 4.6 I-J).

4.4.6 Nox2 Deficiency Increases Apoptosis and Reduces Proliferation
Rate in Endocardial Cushions
ROS regulates cell proliferation and apoptosis in a variety of cell types. Using
immunostaining of cleaved caspase-3, we analyzed cell apoptosis in the endocardial
cushion at E10.5. Nox2 deficiency resulted in a 2 fold higher of apoptosis in the
endocardial cushion (P<0.05, Figure 4.7 A, C). We also assessed cell proliferation using
Ki67 immunostaining. Our data show about 50% lower in cell proliferation rate in the
endocardial cushion of Nox2-/- compared to WT mice (P<0.001, Figure 4.7 B, D).
Furthermore, cellular density in the endocardial cushion of Nox2-/- mice was significantly
lower than the WT controls (P<0.05, Figure 4.8 E).
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Figure 4.6. Gene expression levels in fetal hearts at E10.5.
(A-D) The mRNA levels of Bmp4, Bmp2, Tgfβ2 and Gata4 in Nox2-/- fetal hearts were
significantly lower than WT levels. (E-J) expression levels of Nkx2.5, Gata5, Mef2c, Tbx5,
Notch1 and Tgfβ1 were not altered in Nox2-/- fetal hearts. Data are means ± SEM. N=7-9
hearts per group. At least two hearts were pooled for each sample. *P<0.01 vs. WT by
unpaired Student’s t test.
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Figure 4.7. Increased rate of apoptosis and reduced rate of proliferation in
endocardial cushion (EC) of Nox2-/- hearts at E10.5 and E12.5 respectively.
A) Representative images of histological sections immunostained for cleaved caspase-3 in
E10.5 hearts. Lower panels are enlargement of the boxed areas in upper panels. Arrows
point to positive cells (Brown). B) Representative images of histological sections
immunostained for Ki67 in E12.5 hearts. Lower panels are enlargement of the boxed areas
of upper panels. C) Quantification of cleaved caspase-3 positive cells. D) Quantification of
Ki67 positive cells. E) Quantification of EC cell density at E10.5. *P<0.05 vs. WT.
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4.5 DISCUSSION
NOX2 is a major source of ROS production in cardiomyocytes [15]. It is well
established that excessive ROS production is detrimental to normal embryonic
development [27]. For example, increased ROS levels during pregestational diabetes
result in CHDs in the offspring (Chapter 2). On the other hand, physiological levels of
ROS function as a signalling molecule to promote cardiac differentiation and
cardiomyocyte proliferation [14,28]. However, the role of Nox2-mediated ROS signalling
in embryonic heart development remains unknown. The present study demonstrated that
34% of Nox2-/- neonates had CHDs including septal defects, AVCD, AV valve
malformation, BAV, and impaired remodeling of aortic valves. Importantly, ROS
deficiency resulted in lower EndMT in Nox2-/- endocardial cushions. Pharmacological
inhibition of ROS production in vitro had even lower EndMT of endocardial cushions.
Notably, Nox2 deficiency resulted in lower gene expression including Gata4, Tgfβ2,
Bmp2, Bmp4 and Snail1, which are required for EndMT and endocardial cushion
development. Our study shows for the first time a critical role of NOX2-mediated ROS
signalling in the regulation of EndMT and embryonic heart development (Figure 4.8).
EndMT is a critical process in the formation of endocardial cushions and
valvoseptal development [29]. However, whether NADPH oxidase is essential in the
regulation of EndMT during heart development remains unknown. The present study
provides the following evidence in support of our hypothesis that NOX2-derived ROS
signalling is required for EndMT during embryonic heart development. First of all, Nox2/-

embryos had a lower cellular density in the endocardial cushion at E10.5. Secondly, the
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Figure 4.8. Schematic summary of NOX2 mediated ROS signaling on directing
EndMT and valvoseptal development.
ROS release from NOX2 positively regulates transcript levels of factors that promote
EndMT and formation of normal valvoseptal structures.
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number of cells undergoing EndMT in endocardial cushion explants from Nox2-/embryos was significantly lower. Importantly, treatment with the antioxidant NAcetylcysteine had even lower EndMT in Nox2-/- cushion explants. Thirdly, the
expression of EndMT regulators including Gata4, Tgf-β2, Bmp2 and Bmp4 was markedly
lower in Nox2-/- hearts. Finally, Snail1 expression, a marker of cells undergoing EMT,
was lower in the endocardial cushion of Nox2-/- embryos. Taken together, these data
strongly support a critical role of NOX2-derived ROS signalling in the regulation of
EndMT during embryonic heart development.
BMP2 and BMP4 are inductive signalling molecules that promote EndMT and are
released from the myocardium in the AV canal and OFT regions [22]. Through activation
of BMP receptors on endocardial cells, they increase the expression of Gata4, Tgf-β2 and
Snail1, which are essential for EndMT [30]. In the present study, we demonstrated that
NOX2 is expressed in the myocardium, which includes the AV canal and OFT
myocardium, but not in the endocardium. This pattern of NOX2 expression allows
NOX2-derived ROS to regulate BMP2/4 expression in the myocardium and subsequent
TGF-β signalling in the endocardial cushion. Notably, ROS mediated TGFβ signalling in
the regulation of EMT has been shown in many cell types including keratinocytes [31],
alveolar cells [32] and mammary epithelial cells [33]. The decreased expression of
Bmp2/4, Tgf-β2, and Snail1 in Nox2-/- hearts in the present study supports our hypothesis
that Nox2-derived ROS promotes BMP/TGF-β signalling and EndMT in embryonic heart
development.
Cell proliferation and apoptosis are key cellular events that regulate heart
development during embryogenesis. It is generally believed that excessive levels of ROS
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favor cell apoptosis [34]. Consistent with this notion, we recently showed that increased
ROS production during pregestational diabetes reduces cell proliferation and increases
apoptosis in the endocardial cushion. N-Acetylcysteine restored cell proliferation ration
but not apoptosis (Chapter 2). Surprisingly, lowering ROS levels in control mice by NAcetylcysteine treatment increases cell apoptosis (Chapter 2). In the present study,
deficiency in Nox2 results in lower ROS in E10.5 hearts, higher cell apoptosis and lower
cell proliferation in the endocardial cushion. Our findings suggest that physiological
levels of ROS are critical to cell survival and proliferation during embryonic heart
development. ROS signalling has been shown to induce developmental gene expression
[34]. Thus, lower expression of Gata4, Bmp2/4 and Tgf-β2 observed in the present study
may contribute to higher apoptosis and lower cellular density in the endocardial cushion
of Nox2-/- hearts.
In summary, deficiency in Nox2 results in congenital defects of the septum and
cardiac valves. We further demonstrated that a lack of NOX2-derived ROS production
resulted in lower gene expression in the developing heart and disrupts EndMT with lower
cell proliferation and higher apoptosis in the endocardial cushion. Our data show that
NOX2 is essential in valvoseptal development (Figure 4.8). Notably, patients with
chronic granulomatous disease (CGD) due to NOX gene mutations have ASDs [17]. Our
study provides mechanistic insight into the development of congenital heart defects in
CGD patients and supports a critical role of ROS signaling in embryonic heart
development.
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5. CHAPTER 5
5.1 SUMMARY OF MAJOR FINDINGS
The overall objective of this thesis was to investigate the role of ROS on cardiac
morphogenesis in mice. Specifically, I studied the effect of excess ROS levels on heart
development in the offspring of mice with pregestational diabetes. We aimed to unravel
the molecular mechanisms of cardiovascular defects induced by pregestational diabetes
and provide new insight on potential therapeutic strategies. Additionally, I studied the
role of basal ROS levels in cardiac morphogenesis in non-diabetic pregnancies in Nox2-/mice, which are deficient in ROS production. Experimental approaches included
histological analysis of heart structure, in vitro heart explant cultures and biochemical or
molecular analysis of embryonic hearts.
In Chapter 2, I studied heart development in the offspring of females with
pregestational diabetes and investigated therapeutic strategies to prevent abnormal heart
development. To address this aim, an STZ-induced pregestational diabetes mouse model
was employed. The offspring born to females with pregestational diabetes had lower litter
size, lower body weight and higher mortality at birth. Importantly, a wide spectrum of
CHDs including malformation of septal and conotruncal structures were observed in
neonates. These malformations are comparable to CHDs in the offspring of patients with
pregestational diabetes [1]. Increased incidence of CHDs was associated with oxidative
stress in fetal hearts as evidenced by significantly higher ROS levels and diminished ratio
of reduced to total glutathione levels. Molecular analysis demonstrated altered expression
levels of factors critical to heart development including Gata4, Gata5 and Vegf-a. In
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addition, apoptosis was increased in endocardial cushion and cell proliferation was
markedly reduced in the embryonic hearts affected by maternal diabetes. Furthermore, I
demonstrated for the first time that treatment of diabetic mice with an antioxidant, NAC,
during gestation inhibits oxidative stress in fetal hearts, normalizes gene expression
levels, improves cell proliferation, and decreases the incidence of CHDs in their
offspring. The underlying mechanisms of NAC protection in maternal diabetes induced
CHDs include reductions of ROS levels, elevations of glutathione levels, increases in cell
proliferation, and restoration of altered gene expression profiles.
Formation of coronary arteries is pivotal to myocardial development.
Abnormalities in formation of coronary arteries such as hypoplastic coronary artery
disease increase the risk of sudden cardiac death in youth [2]. In Chapter 3, we
demonstrated for the first time that excess ROS induced by pregestational diabetes led to
coronary artery malformation in the offspring. Histological analysis of fetal and neonatal
hearts exposed to maternal diabetes demonstrated lower diameter and volume of coronary
arteries. Furthermore, pregestational diabetes resulted in abnormal epicardial formation
as evidenced by reduced number of Wt1+ epicardial cells and lower cell proliferation rate.
Additionally, the number of epicardial cells undergoing EMT was lower as evidenced by
Wt1 lineage tracing, immunostaining and in vitro analysis of epicardial EMT in high
glucose culture media. Notably, the expression of HIF1-α, which is a critical
transcriptional regulator of Wt1, was lower in the fetal hearts. Furthermore, the
expression of Wt1 downstream target genes such as ALDH1a2, bFGF, Snail and Slug
was lower in the embryonic heart of diabetic dams. Remarkably, these abnormalities
were all prevented by NAC treatment, leading to normal coronary artery development in
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the offspring of diabetic dams. This study shows that maternal diabetes impairs coronary
artery formation via elevating ROS levels, and provides a rationale for future clinical
studies to investigate pregestational diabetes as a possible cause of hypoplastic coronary
artery disease.
In Chapter 4, I aimed to study the role of basal ROS production in normal heart
development. To achieve this goal, the NADPH oxidase Nox2-/- mouse model was
utilized. Loss of Nox2 resulted in retardation of embryonic growth and lower survival rate
in neonates. Importantly, deficiency of Nox2 resulted in abnormalities in AV septum and
cardiac valves. In particular, Nox2 deficiency resulted in higher cell apoptosis and lower
cell proliferation in the endocardial cushion. In addition, lack of Nox2 impaired EndMT
as evidenced by endocardial cushion cultures ex vivo and lower cellular density in the
endocardial cushion in vivo. Furthermore, treatment with NAC to reduce ROS levels
resulted in lower EndMT in both wild type and Nox2-/- endocardial cushions. Importantly,
Nox2 deficiency resulted in lower transcript levels of Tgf-β2, Bmp2, Bmp4, Snail1 and
Gata4, which are essential in the induction and regulation of EndMT. Overall, this study
demonstrates an important role of NOX2-mediated ROS release in EndMT and
embryonic development of AV septum and cardiac valves.
In Summary, I have demonstrated a pivotal role of ROS signalling in embryonic
heart development. My results show that normal physiological ROS production promotes
cardiogenesis while excessive ROS levels seen in pathological conditions such as
pregestational diabetes induce CHDs. Thus, maintaining a balance of ROS levels is of
critical importance for embryonic heart development. Furthermore, these studies suggest
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a therapeutic potential of NAC in the prevention of CHDs induced by pregestational
diabetes. A summary of these findings is presented in Figure 5.1.

Figure 5.1. Schematic diagram on the role of ROS in regulating heart development
in mice with pregestational diabetes and Nox2 deficiency.
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5.2 STUDY LIMITATIONS
5.2.1 Justification of Diabetes Induced Animal Model
A variety of strategies have been employed to study mechanisms of embryopathy
and CHDs induced by maternal diabetes in animal models. The techniques include
glucose-induced diabetes [3,4], drug-induced diabetes [5-8] and genetic models that
develop diabetes spontaneously [9]. Two important diabetogenic agents are alloxan and
STZ [10,11], which are analogues of glucose and enter pancreatic beta cells via glucose
transporter 2 (GLUT2). Intracellularly, they induce alkylation of DNA that ultimately
leads to oxidative stress and cell death [12]. In comparison to alloxan, STZ maintains
higher levels of drug stability, specificity and efficiency [13,14]. Diabetes induced by
administration of diabetic agents is considered an acute form of type 1 diabetes, where
the onset of diabetes occurs in about ten days following drug administration. To avoid the
risk of STZ teratogenic effects on the fetus, STZ was adminestered to female mice prior
to breeding. The biochemical characteristics of STZ induced diabetes may differ from
clinical cases of patients that progress to diabetes over the years due to genetic changes or
complications from immune deficiencies. An important difference between our
pregestational diabetes mouse model and clinical cases is that diabetic mice did not
receive insulin treatment before or during gestation. As a result, a much higher incidence
of CHDs was observed in our model. Nevertheless, our mouse model demonstrates a
wide spectrum of embryonic defects similar to patient cases. Thus, we believe this is an
excellent mouse model for studying diabetic embryopathy [1].
The offspring of diabetic rodents induced by STZ demonstrate variable
susceptibility to congenital malformation from no congenital malformation to minimal or
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frequent cases [8,15,16]. Part of this variability is due to dose of STZ, animal age and the
time of drug administration in relation to gestation. As an example, if embryos are
affected by maternal diabetes at early gestation congenital defects could occur in central
nervous system or cardiovascular structures and the embryo may demonstrate general
retardation of growth [5]. However, embryos that are affected by maternal diabetes at late
gestational age may suffer from macrosomia, childhood obesity and metabolic disorders
[6]. In addition, variability exists among the offspring of the same litter, which were
exposed to the same level of glucose. It has been suggested that genetic background or
strain variability plays a major role in susceptibility of animals to diabetic embryopathy
[17-19]. Based on our observations and previous reports, C57Bl/6 diabetic mice are
resistance to neural tube defects [17], but are susceptible to CHDs (Chapter 2). The fact
that morphological characteristics of CHDs are comparable to human cases suggests that
the therapeutic strategies can be applied to clinical conditions.

5.2.2 Challenges in Understanding Causes of CHDs Induced by
Diabetes
Reports of increased prevalence of congenital defects in infants of diabetic
women in early1950s [20,21] initiated several experimental studies to elucidate the cause
of diabetic embryopathy. Animal models have been developed to characterize the birth
defects and to investigate their molecular mechanisms [4,8,22,23]. These studies have
shown that hyperglycemia induces biochemical disturbances including oxidative stress in
embryos [24-27]. Advances in molecular analysis have expanded our knowledge of
factors that are altered by maternal diabetes [28]. However, these studies did not fully
clarify the molecular mechanisms of diabetic embryopathy.
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A major challenge in our understanding of diabetic embryopathy is the variable
abnormalities among individuals affected by similar maternal blood glucose levels. This
phenomenon could arise from epigenetic effects of maternal diabetes on the developing
embryo [29,30]. Epigenetic modifications are heritable without any changes in the
genome coding sequence [31]. As an example, microarray analysis revealed altered
expression of over a thousand genes that control transcription, organ morphogenesis or
cell cycle regulation in the heart of diabetic embryos [32,33]. Many of these genes are
target of epigenetic modifications such as histone methylation or acetylation, leading to
inhibition or activation of gene expression [33]. Recent analysis showed increased
intracellular glucose metabolism may elevate acetyl-CoA levels in the nucleus and lead to
excess histone acetylation of DNA[34]. In a separate study, diabetic environment in utero
modulates DNA methylation in the placenta of mice with pregestational diabetes [35].
Other than direct effects of diabetes on embryonic epigenetics, hyperglycemia may
modify epigenetic patterns indirectly by altering the expression of chromatin modifying
factors [36].
Another epigenetic factor, which may interfere with gene expression in diabetic
embryopathy, are non-coding RNAs, such as microRNA. MicroRNA may hybridize with
complementary mRNA sequences and interfere with their translation. Cell culture
experiments demonstrated high glucose alters levels of microRNAs in vitro, thus
interferes with translation of mRNAs [37]. In addition, retrospective analysis of genes
that are altered by maternal diabetes revealed that majority of them are targets of at least
one microRNA [33,38]. According to these studies hyperglycemia or high glucose
conditions increase the risk of epigenetic alterations [39]. These results challenged
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identifying a distinct molecular mechanism that defines a causal relationship between
hyperglycemia-induced alterations of gene expression and embryonic defects.
Nevertheless, the experimental analysis provided in this thesis demonstrates that
antioxidant treatments normalize gene expression levels and reduced the incidence of
CHDs. These results support our hypothesis that oxidative stress is the main cause of
CHDs induced by maternal diabetes.

5.3 SUGGESTIONS FOR FUTURE RESEARCH
Insulin treatment to diabetic women reduces the risk of congenital defects in
newborns [40,41]. Therefore, women with pregestational diabetes are strongly advised to
plan their pregnancy and control their glucose levels by insulin injections or medications
prior to conception and during gestation [42]. It should be noted that pregnancy alters
glucose metabolism and insulin sensitivity, thus, achieving optimal glycemic control in
diabetic women is challenging [43]. Because of this, the risk of birth defects in insulin
treated diabetic women is still higher than non-diabetic population [44,45], indicating that
insulin alone is not sufficient to protect against congenital defects in the offspring of
diabetic women. In this thesis, we overcome this challenge by demonstrating the
protective effect of NAC in reducing the risk of birth defects in the offspring of noninsulin treated pregestational diabetic mice. Future studies should also investigate the
effects of insulin treatment on CHDs induced by pregestational diabetes in mice.

5.3.1 Therapeutic Potential of NAC on Prevention of CHD
Birth defects induced by pregestational diabetes are highly attributed to increased
ROS levels and reduced antioxidant levels. Thus, an important therapeutic strategy of
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diabetic embryopathy is replenishing antioxidant capacity of the embryo. Previous
studies on diabetic embryopathy reported deficiencies of glutathione or antioxidant levels
in embryos. Vitamins C, E and folic acid have the ability to scavenge free oxygen
radicals [46,47] and their efficiency in diminishing embryonic malformation has been
demonstrated in diabetic animal models [48-53]. NAC is a derivative of amino acid
cysteine, which is an intracellular source of glutathione [54]. In pathological conditions
where GSH levels are diminished, NAC treatment demonstrates higher efficiency and
consistency in replenishing GSH levels in comparison to cysteine or glutathione. Oral
treatment of glutathione does not increase plasma levels of cysteine or glutathione
effectively due to enzymatic actions that hydrolyze glutathione in the digestive tract [55].
Likewise, cysteine oxidizes promptly in oxygenated extracellular environment, and only
some cells have the ability to import the oxidized cysteine and reduce it [56]. In addition,
systemic administration of cysteine shows disruptive effects on neurons of the central
nervous system [57,58]. Remarkably, the acetyl group of NAC protects it against
oxidation or hydrolysis and can efficiently elevate glutathione bioavailability [59]. NAC
has been used in several pathological conditions to rescue GSH deficiency and inhibit
oxidative stress [59]. Previous studies demonstrated in vitro or in ovo treatment of NAC
reduces the rate of congenital defects in embryos induced by high glucose [60,61].
Additionally, treatment with GSH-ester decreases outflow tract defects induced by
maternal diabetes [62]. We investigated whether oral treatment of NAC in diabetic
females during gestation prevents the incidence of CHDs in their offspring. Remarkably,
NAC treatment successfully elevated total and reduced GSH levels in fetal hearts of
embryos of diabetic dams and prevented the development of CHDs (Chapter 2).
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Additionally, NAC adminstration restore transcript levels in embryos affected by
pregestaional diabetes. Previous studies demontrated that NAC can alter proteins activity
and transcript levels of many genes [10]. Whether gene expression levels are directly
affected by NAC or intracellular glutathione levels or as an indirect effect of reduced
oxidative stress remains to be investigated. Further experimental analysis is also required
to expand our knowledge on the pharmacokinetics of NAC prior to its application for
clinical studies.
Although NAC is generally considered a safe antioxidant, cautions should be
taken in prescribing the right dose of NAC to pregnant women. Our experimental
analysis demonstrated a slight increase in the rate of CHDs (10%) in the control offspring
by NAC treatment. Although this was not statistically significant due to a small sample
size, it suggests that reduction of ROS levels below normal physiological levels may also
be detrimental to normal heart development. Additionally, exposure to higher
concentrations of NAC induces reductive stress, as evidenced by mitochondrial oxidation
and elevated cytotoxicity in cultured cells [63]. In agreement with this notion, a high dose
of NAC in rats has been shown to reduce fertility in females [64]. However, with the dose
used in our studies, we did not observe any difference in pregnancy success rate between
groups. Thus, dosage of NAC treatment should be carefully examined in further animal
studies before initiating clinical trials.
NAC from the maternal circulation can cross the placenta and reach the
developing embryos [65]. However, a possible impact of antioxidant activities of NAC
on other maternal organs including kidneys, liver and pancreas should not be neglected.
Our studies demonstrated that NAC has beneficial effects on metabolism as shown by
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reduced food and water intake in the diabetic mice (Chapter 2). A small but nonsignificant reduction of blood glucose levels in diabetic females was also observed with
NAC treatment. It is possible that NAC may have beneficial effects on insulin release or
insulin sensitivity. Further studies are required to study these effects and associated
molecular mechanisms of NAC.
As discussed before, maternal diabetes impairs embryonic development through
multiple signalling pathways. Previous experimental studies demonstrated
supplementation of folic acid, vitamin C or E reduces the risk of birth defects in diabetic
pregnancies [48-53]. Here, we demonstrated that NAC is a potent molecule that protects
embryos against oxidative stress induced by maternal diabetes. It is possible that a
combination of folic acid, vitamins and NAC may have a synergistic benefit on the
prevention of birth defects in the offspring of women with pregestational diabetes. To test
this hypothesis, further pre-clinical and clinical studies are required to investigate the
appropriate dose and their efficiency in preventing birth defects induced by maternal
diabetes.

5.3.2 Role of NOX2 in Heart Development
NOX2 and NOX4 are expressed in both adult cardiomyocytes and cardiac stem
cells, but are distinctly localized on the plasma membrane and mitochondrial cell
membrane, respectively [66,67]. In Chapter 4, we demonstrated that NOX2 mediated
ROS release regulates Tgf-β/Bmp signalling and promotes EndMT required for cardiac
septum and valve development. Furthermore, we demonstrated during early heart
development (E10.5) NOX2 expression pattern is more robust in the left ventricular
myocardium compared to the right (Figure 4-3). While cellular and molecular
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characteristics of cardiomyocytes of the right and left ventricle are distinct [68],
understanding the regulators of this distinct gene expression profile become an essence in
topics such as induction of embryonic stem cells differentiation to cardiomyocyte.
Previous studies have demonstrated an important role of NOX4 in the regulation of
cardiac stem cell differentiation [67]. Whether ROS release from NOX2 regulates cardiac
differentiation in the same or a different mechanism is not known. Thus, an interesting
extension to studies performed in Chapter 4 is to evaluate the role of ROS released from
NOX2 or 4 in the regulation of factors essential for cardiomyocyte differentiation. This
can be performed primarily by evaluation of temporal and spatial expression of NOX2
and NOX4 during cardiogenesis in the embryos. Followed by this, the effect of NOX2
expression or inhibition in embryonic stem cells in relation to gene expression levels has
to be investigated. Distinct expression pattern of NOX proteins might imply different role
of ROS released from each source. Further studies are required to examine the temporal
and spatial expression of NOX family and their contributions to cardiomyocyte
differentiation and proliferation.

5.4 CONCLUSION
This thesis provides evidence of a pivotal role of ROS signalling in the regulation
of embryonic heart development. Here, I demonstrated that excess ROS levels induced by
pregestational diabetes alter gene expression profiles required for cardiovascular
development and thus lead to CHDs in the offspring. Additionally, I have shown that
treatment with an antioxidant, NAC, restores altered gene expression and reduces the
incidence of CHDs in the diabetic offspring. Furthermore, this thesis provided valuable
insight into a critical role of basal ROS levels in promoting EndMT and heart
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development. Overall, my doctoral research thesis has broadened our understanding of
ROS levels on heart morphogenesis and our findings may have implications in the
clinical prevention and treatment of CHDs during pregestational diabetes.
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